Estradiol Vaginal Ring (Estring) - Complete Clinical Reference

Document Status: Complete Comprehensive Research Paper Last Updated: December 24, 2025 Intended Use: Clinical reference for healthcare providers and patient education

1. Summary

1.1 Overview

Estring (estradiol vaginal ring) is a low-dose, locally acting vaginal estrogen product FDA-approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy (VVA) due to menopause, also known as genitourinary syndrome of menopause (GSM). Estring is a silicone elastomer ring containing 2 mg of estradiol that, when placed in the vaginal vault, releases approximately 7.5 mcg of estradiol per 24 hours continuously for 90 days.

Brand Name: Estring Generic Name: Estradiol vaginal ring Drug Class: Vaginal estrogen Route: Intravaginal (locally acting) FDA Approval: 1996 Manufacturer: Pfizer Inc.

Goal Relevance:

• I want to relieve vaginal dryness and discomfort during menopause.
• I'm looking for a solution to improve painful intercourse due to menopause.
• I need a long-lasting treatment for vaginal health without daily hassle.
• I want to maintain vaginal health with minimal systemic hormone exposure.
• I'm seeking a discreet and comfortable option for managing menopause symptoms.
• I need a non-messy alternative to creams for vaginal atrophy.
• I want to normalize vaginal pH and improve overall vaginal health during menopause.

1.2 Key Features

Unique Delivery System:

• 90-day continuous release - One ring lasts 3 months, eliminating daily application
• 7.5 mcg/24h estradiol - Consistent, low-dose delivery maintains therapeutic vaginal tissue levels
• Minimal systemic absorption - Only ~8% of released estradiol absorbed systemically; serum levels remain within postmenopausal range

Clinical Advantages:

• High efficacy for VVA - 80-85% improvement in vaginal dryness, dyspareunia, vaginal pH normalization
• Superior convenience - Quarterly replacement vs daily cream/tablet application
• Low side effect profile - Minimal systemic effects; no endometrial hyperstimulation in clinical trials
• Discrete and comfortable - Invisible, flexible ring; most women and partners do not feel ring during intercourse

Comparison to Other Vaginal Estrogens:

• vs Vaginal Cream: Equal efficacy, superior convenience (90 days vs daily), less messy
• vs Vaginal Tablets (Vagifem): Equal efficacy, longer duration (90 days vs 7-14 days initial, then twice weekly)
• vs Femring: Lower dose (7.5 mcg vs 50-100 mcg/day); Estring is local-only, Femring has systemic effects

1.3 Clinical Efficacy

Vulvovaginal Atrophy Symptoms:

Patient Satisfaction: 83% satisfied or very satisfied (vs 82% with vaginal cream, 85% with Vagifem)

1.4 Safety Profile

Low Systemic Exposure:

• Mean serum estradiol levels: 7.8 pg/mL (within postmenopausal range: 5-22 pg/mL)
• Minimal increase in estrone levels
• No increase in endometrial thickness - Zero cases of endometrial hyperstimulation in clinical trials (vs 11% with vaginal cream)

Progestin NOT Required:

• Due to minimal systemic absorption, progestin co-administration not recommended for Estring users with intact uterus
• Contrast with systemic HRT where progestin mandatory

Minimal Systemic Side Effects:

• No significant increase in VTE risk (local-only therapy)
• No cardiovascular risk increase
• No effect on breast tissue (minimal systemic estrogen)

Common Local Side Effects (5-15%):

• Vaginal discomfort or irritation
• Increased vaginal discharge
• Vaginal infection (bacterial vaginosis, candidiasis)
• Ring expulsion (rare, <10%)

1.5 Contraindications

Absolute Contraindications:

• Known, suspected, or history of breast cancer
• Known or suspected estrogen-dependent neoplasia
• Active or history of VTE (DVT, pulmonary embolism)
• Active or history of arterial thromboembolism (stroke, MI)
• Liver dysfunction or disease
• Undiagnosed abnormal genital bleeding
• Hypersensitivity to estradiol or ring components
• Pregnancy

Relative Contraindications:

• Endometriosis
• Uterine fibroids
• Hypercalcemia
• Thrombophilic disorders

Important Note: While breast cancer is listed as contraindication in labeling, some specialists consider low-dose vaginal estrogen (like Estring) in select breast cancer survivors with severe VVA refractory to non-hormonal therapies, after oncology consultation. This is controversial and off-label.

1.6 Cost and Accessibility (2025)

Pricing:

• Retail cash price: $662-$750/ring (90-day supply)
• GoodRx discount: $249-$280/ring (~62% savings)
• International pharmacy: $137/ring (PharmacyChecker-accredited)

Cost Comparison:

• Estring: $2.77-$8.33/day
• Vaginal cream (generic): $1.33-$3.00/day
• Vagifem 10 mcg: $3.00-$6.00/day

Generic Availability: NO generic as of 2025; unknown when generic will be available

Insurance Coverage:

• Covered by most commercial insurance plans (copay $30-$100)
• Covered by ~50% of Medicare Part D plans
• Medicaid coverage varies by state

Manufacturer Savings Program (2025):

• Eligible patients pay $45/ring (commercially insured only, not Medicare/Medicaid)
• Savings up to $100/fill (4 fills max, $400 annual maximum)

1.7 When to Choose Estring

Ideal Candidates:

• Postmenopausal women with moderate-severe VVA symptoms (vaginal dryness, dyspareunia)
• Prefer convenience of 90-day application vs daily cream/tablets
• Concerned about systemic estrogen exposure (e.g., breast cancer survivors seeking local-only therapy, though still controversial)
• Unable to tolerate messiness of vaginal cream
• Sexually active (ring can remain in place during intercourse)

Not Ideal For:

• Women with VVA + moderate-severe vasomotor symptoms (hot flashes) - Consider systemic HRT or Femring
• Women unable to insert/remove vaginal ring (physical dexterity limitations) - Consider cream or tablets
• Cost-sensitive patients without insurance - Generic vaginal cream significantly cheaper

1.8 Clinical Bottom Line

Estring is a highly effective, convenient, and safe low-dose vaginal estrogen product for treating VVA in postmenopausal women. Its 90-day duration, minimal systemic absorption, and lack of endometrial stimulation make it an attractive option for long-term management of vaginal atrophy. The lack of generic availability and relatively high cost are the primary limitations. For women who can afford it or have insurance coverage, Estring offers excellent symptom relief with superior convenience compared to daily vaginal creams or tablets.

2. Mechanism of Action

2.1 Estrogen Receptor Binding

Estring delivers 17β-estradiol, the most potent naturally occurring estrogen, directly to vaginal tissues.

Molecular Mechanism:

1. Estradiol diffuses from ring into vaginal epithelium
2. Binds to estrogen receptors (ER-α and ER-β) in target tissue cells
   • Vaginal epithelium: High concentration of ER-α
   • Urethral epithelium: Significant ER-α and ER-β expression
   • Bladder trigone: ER-β predominant
3. Estrogen-receptor complex translocates to cell nucleus
4. Binds to estrogen response elements (EREs) on DNA
5. Activates gene transcription → Protein synthesis
   • Increases production of structural proteins (collagen, elastin)
   • Upregulates growth factors (TGF-β, VEGF)
   • Enhances glycogen synthesis in vaginal epithelium

Result: Proliferation, maturation, and vascularization of vaginal and urethral epithelium

2.2 Vaginal Tissue Effects

Estring reverses the atrophic changes of menopause:

2.2.1 Epithelial Proliferation

Pre-Treatment (Atrophic):

• Thin epithelium (few cell layers, predominantly parabasal cells)
• Reduced glycogen content
• Pale, dry appearance
• Fragile, easily traumatized

Post-Estring Treatment:

• Thickened epithelium - Increased cell layers (15-20 layers vs 3-5 in atrophy)
• Cell maturation - Shift from parabasal → intermediate → superficial cells
  • Maturation index improves: Increased % superficial cells (marker of estrogenization)
• Increased glycogen storage in superficial cells
• Improved barrier function - Reduced risk of micro-abrasions, infection

2.2.2 Vaginal pH Normalization

Mechanism of pH Restoration:

Estrogen Deficiency (Postmenopause):

• Low glycogen → Lactobacillus bacteria cannot thrive
• Loss of vaginal lactobacilli → No lactic acid production
• Vaginal pH rises to 6.0-7.0 (alkaline)
• Alkaline environment allows pathogenic bacteria overgrowth (E. coli, anaerobes)

Estring Treatment:

• Restores glycogen production in vaginal epithelium
• Glycogen is metabolized by Lactobacillus species → Lactic acid production
• Vaginal pH decreases to 4.5-5.5 (acidic, similar to premenopausal range)
• Acidic pH inhibits pathogenic bacteria, reduces UTI risk

Clinical Data:

• Baseline pH: 6.0-7.0
• Post-Estring (12 weeks): pH 4.6 (mean)
• 90% of women achieve pH <5.5

2.2.3 Lubrication and Secretion

Estrogen stimulates vaginal transudation and glandular secretion:

Mechanisms:

1. Increased blood flow → Enhanced plasma transudation through vaginal epithelium
   • Estrogen induces VEGF (vascular endothelial growth factor) → Angiogenesis
   • More capillaries → Increased perfusion → More transudate
2. Cervical mucus production (if cervix present)
   • Estrogen stimulates cervical glands → Mucus secretion
3. Bartholin's gland activity (vulvovaginal glands)
   • Estrogen enhances gland secretion → Additional lubrication

Result: Improved vaginal lubrication, reduced vaginal dryness, reduced dyspareunia

2.2.4 Elasticity and Rugae Restoration

Estrogen promotes collagen and elastin synthesis:

Structural Changes:

• Collagen production increases → Improved tissue strength, reduced fragility
• Elastin fibers restored → Improved elasticity (vaginal distensibility)
• Rugae (folds) reappear on vaginal walls → Increased surface area, better accommodation during intercourse

Clinical Significance: Reduced risk of vaginal tearing, micro-abrasions, bleeding with intercourse or examination

2.3 Urogenital Effects (Beyond Vagina)

Estrogen receptors are present throughout the urogenital tract:

2.3.1 Urethral Effects

Urethral epithelium contains high concentrations of estrogen receptors.

Estring Benefits for Urethra:

• Urethral epithelial thickening → Improved mucosal seal
• Increased urethral blood flow → Enhanced tissue health
• Improved urethral closure pressure → Reduced stress urinary incontinence (controversial benefit)

Clinical Evidence: Some studies show reduction in recurrent UTIs with vaginal estrogen (Estring included), attributed to urethral epithelial restoration and pH normalization reducing bacterial colonization.

2.3.2 Bladder Trigone

Bladder trigone (base of bladder) expresses ER-β receptors.

Potential Effects:

• Improved sensory function (reduced urgency)
• Possible reduction in overactive bladder symptoms (limited evidence)
• Enhanced urothelial integrity

Note: Evidence for Estring improving urinary symptoms (urgency, frequency, incontinence) is MIXED. Primary benefit is for VVA and possibly recurrent UTI reduction, NOT primary urinary incontinence treatment.

2.4 Systemic Absorption and Metabolism (Minimal)

Estring is designed as a LOCAL therapy with minimal systemic effects.

2.4.1 Absorption

Local Delivery:

• 7.5 mcg estradiol released into vaginal vault per 24 hours
• Only ~8% absorbed systemically (95% CI: 2.8-12.8%)
• Remaining estradiol acts locally on vaginal/urethral tissue or is lost through vaginal discharge

Systemic Levels:

• Peak serum estradiol: Brief spike to ~25-40 pg/mL at insertion (0.5-1 hour Tmax)
• Steady-state serum estradiol: 7.0-8.1 pg/mL (within postmenopausal range: 5-22 pg/mL)
• Serum levels virtually indistinguishable from untreated postmenopausal women after 24 hours

Comparison to Systemic HRT:

• Oral estradiol: Target serum levels 40-100 pg/mL
• Transdermal estradiol gel/patch: Target 30-80 pg/mL
• Estring: 7-8 pg/mL (no systemic target - local therapy)

2.4.2 Metabolism (Minimal)

Due to low systemic absorption, metabolism is minimal and similar to endogenous estradiol:

Hepatic Metabolism:

• CYP1A2, CYP3A4 - Hydroxylation to estrone, estriol, catechol estrogens
• Conjugation - Sulfation and glucuronidation to water-soluble metabolites

Enterohepatic Circulation:

• Conjugated estrogens excreted in bile
• Deconjugation in gut by bacterial β-glucuronidase
• Reabsorption (minimal due to low systemic levels)

Excretion:

• Primarily renal (conjugated metabolites in urine)
• Fecal elimination of unabsorbed estradiol from vaginal discharge

Clinical Implication: Because systemic absorption is so low, drug interactions affecting hepatic metabolism (CYP3A4 inducers/inhibitors) have minimal clinical significance with Estring, unlike systemic HRT.

2.5 Why Local Estrogen Works Without Systemic Effects

Estring achieves therapeutic vaginal tissue levels WITHOUT raising serum estradiol to systemic HRT levels.

Mechanism:

1. High local concentration in vaginal epithelium from direct contact with ring
2. Slow systemic absorption - Only ~8% absorbed; most estradiol remains local or lost in discharge
3. First-pass vaginal metabolism - Some estradiol metabolized locally before entering systemic circulation
4. Equilibrium favors local action - Constant low-dose release maintains therapeutic vaginal levels without accumulation in serum

Clinical Result:

• Vaginal estradiol tissue levels: High (therapeutic)
• Serum estradiol levels: Low (postmenopausal range)
• Benefit: Local VVA symptom relief WITHOUT systemic effects (endometrial stimulation, breast stimulation, VTE risk)

3. Indications and Usage

3.1 FDA-Approved Indication

Estring is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.

Regulatory Status:

• FDA Approval: 1996
• Regulatory Class: Prescription-only (Rx)
• Indication: VVA symptom relief (NOT for systemic estrogen replacement, NOT for vasomotor symptoms)

Important: FDA requires that estrogen-containing products be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

3.2 Symptoms of Vulvovaginal Atrophy (VVA) / Genitourinary Syndrome of Menopause (GSM)

VVA (now commonly termed GSM) is a chronic, progressive condition affecting 40-60% of postmenopausal women.

Primary Symptoms Estring Treats:

3.2.1 Vaginal Dryness

Most common VVA symptom (75-80% of women with VVA):

• Persistent sensation of dryness in vaginal vault
• Discomfort with daily activities (sitting, walking)
• Worsens with physical activity, tight clothing

Estring Efficacy: 83% improvement rate (physician/patient global assessment)

3.2.2 Dyspareunia (Painful Intercourse)

Second most common symptom (40-60% of postmenopausal women):

• Pain with vaginal penetration
• Burning, tearing sensation during intercourse
• Post-coital soreness
• Often leads to sexual avoidance, relationship strain

Mechanisms:

• Thin, fragile vaginal epithelium → Micro-abrasions, tearing
• Reduced lubrication → Friction, irritation
• Loss of elasticity → Inadequate accommodation

Estring Efficacy: ~80% improvement in dyspareunia severity

3.2.3 Vaginal Irritation and Itching

Common complaints:

• Burning sensation (vulva and vagina)
• Pruritus (itching) - Often misattributed to yeast infection
• Sensation of irritation without obvious cause

Mechanism: Thinned epithelium more susceptible to irritation from:

• Urine contact
• Clothing friction
• Hygiene products (soaps, wipes)
• pH imbalance

Estring Benefit: Epithelial thickening reduces sensitivity, irritation resolves

3.2.4 Vaginal Bleeding/Spotting

Vaginal bleeding with minimal trauma:

• Post-coital bleeding (most common)
• Bleeding with pelvic examination
• Spontaneous spotting (less common)

Mechanism: Thin, friable epithelium → Easy micro-trauma → Bleeding

Important: New vaginal bleeding MUST be evaluated to rule out endometrial or cervical pathology before attributing to VVA.

Estring Effect: Epithelial thickening reduces fragility, bleeding resolves

3.3 Patient Selection Criteria

Ideal Candidates for Estring:

3.3.1 Postmenopausal Status

Estring is for postmenopausal women only.

Menopause Definition:

• Natural menopause: 12 months of amenorrhea (no menstrual periods) after final menstrual period
• Surgical menopause: Bilateral oophorectomy (removal of both ovaries)
• Age: Typically ≥50 years (average age of menopause 51 years in U.S.), but earlier in surgical/premature menopause

Confirmation (if uncertain):

• FSH level >30-40 IU/L (postmenopausal range)
• Estradiol <20 pg/mL (postmenopausal)

Note: Estring can be used in younger women with premature ovarian insufficiency (POI) or surgical menopause.

3.3.2 Moderate to Severe VVA Symptoms

Estring is indicated for moderate-severe symptoms, NOT mild symptoms.

Severity Classification:

Mild VVA:

• Occasional vaginal dryness
• No dyspareunia or minimal discomfort
• Minimal impact on quality of life
• Management: Non-hormonal lubricants/moisturizers first-line

Moderate VVA:

• Frequent vaginal dryness affecting daily comfort
• Dyspareunia present, limits sexual activity
• Vaginal irritation/burning
• Management: Vaginal estrogen (Estring) or non-hormonal therapies if estrogen contraindicated

Severe VVA:

• Constant vaginal dryness, significant discomfort
• Severe dyspareunia preventing intercourse
• Vaginal bleeding with intercourse
• Significant impact on quality of life
• Management: Vaginal estrogen (Estring) is first-line

3.3.3 Preference for Long-Acting, Convenient Therapy

Estring is ideal for women who:

• Prefer infrequent dosing (90-day ring vs daily cream/tablets)
• Dislike messiness of vaginal cream
• Are comfortable with vaginal insertion (similar to tampon use)
• Sexually active and prefer product that remains in place during intercourse

Not Ideal For:

• Women uncomfortable with vaginal insertion/removal
• Women with vaginal stenosis (narrowing) preventing ring placement
• Severe pelvic organ prolapse (ring may be expelled)

3.4 Off-Label Uses (Not FDA-Approved)

3.4.1 Recurrent Urinary Tract Infections (UTIs)

Rationale:

• Vaginal estrogen restores vaginal pH, promotes lactobacilli colonization
• Reduces uropathogenic bacteria (E. coli) colonization in vaginal/urethral area
• May reduce recurrent UTI incidence in postmenopausal women

Evidence:

• Some studies show 30-50% reduction in recurrent UTI rates with vaginal estrogen (including Estring)
• 2019 AUA guidelines: Vaginal estrogen recommended for postmenopausal women with recurrent UTIs

Note: This is OFF-LABEL use. Primary indication remains VVA symptom relief.

3.4.2 Lichen Sclerosus (Vulvar)

Controversial use:

• Some clinicians use vaginal estrogen as adjunct to topical corticosteroids for lichen sclerosus
• Limited evidence for efficacy
• First-line treatment remains high-potency topical corticosteroids (clobetasol propionate)

Estring Limitation: Estring delivers estrogen primarily to vagina; minimal delivery to vulvar skin (where lichen sclerosus occurs). Vaginal cream may be preferable if estrogen used for vulvar conditions.

3.4.3 Sexual Dysfunction / Low Libido

Estring can improve dyspareunia → May indirectly improve sexual function and desire by reducing pain.

However:

• Estring does NOT directly increase libido (minimal systemic estrogen, no testosterone)
• For low libido, consider:
  • Addressing psychosocial factors (relationship issues, body image)
  • Systemic estrogen (if VMS also present)
  • Testosterone therapy (off-label in postmenopausal women with hypoactive sexual desire disorder)

3.5 When NOT to Use Estring (See Contraindications - Section 8)

Do NOT use Estring if:

• Active or history of breast cancer (absolute contraindication per labeling, though some specialists reconsider in select cases)
• Active VTE or arterial thromboembolism
• Undiagnosed vaginal bleeding (must rule out malignancy first)
• Known estrogen-dependent neoplasia (endometrial cancer, ovarian cancer)
• Liver dysfunction/disease
• Pregnancy (extremely unlikely in postmenopausal women, but contraindicated)

4. Dosing and Administration

4.1 Standard Dosing

Estring is a "one size fits all" product - there is only ONE dose available:

Product Specifications:

• Estradiol content: 2 mg per ring (in core reservoir)
• Release rate: ~7.5 mcg/24 hours
• Duration: 90 days continuous release
• Replacement schedule: Every 3 months

Dosing Instructions:

1. Insert ONE Estring ring into vaginal vault
2. Leave in place for 90 days (3 months)
3. Remove ring after 90 days
4. If continuing therapy: Insert new ring immediately after removing old ring
5. If discontinuing: Remove ring and do not replace

No dose titration: Unlike systemic HRT (where dose can be adjusted), Estring has fixed release rate. Cannot "increase dose" by using 2 rings or "decrease dose" by removing early.

4.2 Initiation of Therapy

4.2.1 Pre-Insertion Evaluation

Before prescribing Estring:

1. Confirm postmenopausal status (12 months amenorrhea or surgical menopause)

2. Assess symptom severity (moderate-severe VVA required for indication)

3. Rule out contraindications (see Section 8)

4. Exclude pathology:

   • If abnormal vaginal bleeding present → Endometrial assessment (ultrasound/biopsy) BEFORE starting Estring
   • Pelvic examination to assess degree of atrophy, rule out masses/prolapse

5. Treat active vaginal infections BEFORE Estring insertion:

   • Bacterial vaginosis → Metronidazole
   • Candidiasis → Fluconazole or topical antifungal
   • Estring can be started after infection treated

6. Informed consent: Discuss benefits, risks, alternatives

4.2.2 Patient Instructions for Insertion

Estring can be inserted by the patient or healthcare provider. Most women self-insert.

Self-Insertion Steps (Similar to Tampon Use):

Preparation:

1. Wash and dry hands thoroughly
2. Remove Estring from foil pouch using tear-off notch
3. Choose comfortable position:
   • Standing with one leg elevated (foot on chair/toilet)
   • Squatting
   • Lying down

Insertion:

1. Hold Estring between thumb and index finger
2. Press ring sides together to form narrow oval (makes insertion easier)
3. Insert compressed ring into vagina, pushing gently upward and backward
4. Push ring as far back as comfortable - Aim for upper one-third of vaginal vault
5. Release ring - It will expand to its original shape in vagina

Positioning:

• Exact position is NOT critical - Ring does not need to be placed in specific location
• If positioned correctly, you should NOT feel the ring once in place
• If you feel discomfort → Ring likely not inserted far enough → Use finger to push further back

What to Expect:

• Ring should remain in place during normal activities, urination, bowel movements
• Most women (and partners) do NOT feel ring during intercourse

4.3 Ongoing Use

4.3.1 Continuous Wear for 90 Days

Estring is designed to remain in place continuously for 3 months.

Do NOT remove except:

• During 90-day replacement
• If vaginal infection develops (see Section 4.3.3)
• If ring causes discomfort or falls out (see Section 4.3.2)

No need to remove for:

• Intercourse (ring can stay in place - most couples do not feel it)
• Bathing, swimming, exercise
• Pelvic examination (provider may remove temporarily for full visualization, then replace)

4.3.2 What If Ring Falls Out or Is Removed?

Ring Expulsion:

• Occurs in <10% of women
• Most common in first few weeks (before vaginal epithelium thickens)
• Risk factors: Severe vaginal atrophy, pelvic organ prolapse, chronic constipation (straining)

If Ring Falls Out:

1. Rinse ring in lukewarm (NOT hot) water
2. Reinsert immediately (while hands clean)
3. If unable to reinsert → Contact healthcare provider for assistance

If Ring Removed for Any Reason (e.g., during intercourse):

1. Rinse in lukewarm water
2. Reinsert promptly

Duration of Removal:

• Short-term removal (few hours) → No significant impact on efficacy
• If ring out >24 hours → May reduce therapeutic effect; consider replacing sooner than 90 days

4.3.3 Ring Removal During Vaginal Infection

If vaginal infection develops while using Estring:

Symptoms of Vaginal Infection:

• Increased discharge (unusual color, odor)
• Itching, burning
• Vulvar irritation

Management:

1. Remove Estring temporarily
2. Diagnose infection:
   • Bacterial vaginosis (BV) - Fishy odor, thin gray discharge, pH >4.5
   • Candidiasis (yeast) - Thick white cottage-cheese discharge, itching
3. Treat infection:
   • BV: Metronidazole 500 mg PO BID × 7 days OR metronidazole gel 0.75% intravaginally × 5 days
   • Candidiasis: Fluconazole 150 mg PO × 1 dose OR miconazole intravaginal × 3-7 days
4. Reinsert Estring after infection resolved (typically 1 week)

Note: Do NOT count time ring was out toward the 90-day duration. If ring removed for >1 week due to infection, may need to replace ring sooner or use new ring after reinsertion.

4.4 Ring Removal and Replacement (90-Day Cycle)

4.4.1 Removal Instructions

After 90 days, Estring must be removed and replaced (if continuing therapy).

Removal Steps:

1. Wash and dry hands
2. Assume comfortable position (squatting, standing with one leg up, or lying down)
3. Insert index finger into vagina and hook finger through center of ring
4. Pull ring downward and outward gently
5. If difficulty grasping ring → Try bearing down (Valsalva) to bring ring closer to vaginal opening, then hook finger through ring

If Unable to Remove:

• Contact healthcare provider - Provider can remove ring using finger or instrument (ring forceps)

4.4.2 Disposal of Used Ring

Do NOT flush ring down toilet (environmental contamination)

Proper Disposal:

1. Place used ring in original foil pouch (if available) or sealed plastic bag
2. Discard in household trash
3. Keep out of reach of children and pets

Environmental Note: Estradiol can persist in water systems; flushing hormone-containing products contributes to environmental estrogen contamination affecting aquatic life. Always dispose in trash.

4.4.3 Insertion of New Ring

If continuing therapy:

• Insert new Estring ring immediately after removing old ring (same day)
• No "ring-free interval" required (unlike contraceptive vaginal rings)

If discontinuing therapy:

• Simply remove old ring and do not replace
• VVA symptoms may gradually return over weeks to months after discontinuation

4.5 Duration of Therapy

How long should Estring be used?

FDA Labeling:

• "The need for continued therapy should be assessed at 3 to 6 month intervals."

Clinical Practice:

• VVA is a chronic condition - Symptoms typically return within weeks to months after discontinuing estrogen
• Many women use Estring indefinitely (years to decades) if benefits outweigh risks
• Reassess need every 6-12 months:
  • Are symptoms controlled?
  • Any adverse effects?
  • Any new contraindications developed (e.g., breast cancer diagnosis)?
  • Patient still desires therapy?

2024 NAMS Position:

• "No arbitrary time limit for duration of vaginal estrogen therapy."
• "Women can continue vaginal estrogen as long as symptoms persist and benefits outweigh risks."

Practical Approach:

• If VVA symptoms well-controlled and no adverse effects → Continue indefinitely
• Attempt discontinuation only if patient desires or new contraindication arises

4.6 Missed Dose / Delayed Replacement

What if 90-day replacement is delayed?

Estring continues to release some estradiol beyond 90 days, but release rate declines:

• Days 1-90: ~7.5 mcg/24h (consistent)
• Days 90-120: Declining release rate
• Beyond 120 days: Minimal release

If Replacement Delayed:

• 1-2 weeks late: Remove old ring, insert new ring immediately - Minimal symptom recurrence expected
• >2 weeks late: VVA symptoms may start returning - Remove old ring, insert new ring; symptoms should improve within 1-2 weeks

Recommendation: Set calendar reminder for 90-day replacement to maintain consistent symptom control.

4.7 Switching from Other Vaginal Estrogen Products

If patient currently using vaginal cream or tablets and switching to Estring:

From Vaginal Cream:

1. Discontinue cream
2. Insert Estring within 1 week of last cream dose
3. No washout period needed

From Vaginal Tablets (Vagifem):

1. Discontinue tablets
2. Insert Estring within 3-7 days of last tablet
3. No washout period needed

Rationale: All vaginal estrogen products have minimal systemic absorption; no risk of "overdose" from overlapping therapy.

4.8 Use During Intercourse

Estring can remain in place during intercourse.

Patient Counseling:

• Most women and partners do NOT feel ring during intercourse
• Ring position may shift during intercourse but will not "get lost" (vagina is closed space)
• If ring causes discomfort for patient or partner → Can remove before intercourse, rinse, and reinsert after

Important: If removing ring for intercourse, limit removal time to <2-3 hours to maintain therapeutic effect.

5. Pharmacokinetics

5.1 Absorption

Estring is designed for LOCAL vaginal action with MINIMAL systemic absorption.

5.1.1 Local Delivery

Release Kinetics:

• Release rate: 7.5 mcg estradiol per 24 hours (approximately)
• Total estradiol in ring: 2 mg (2,000 mcg)
• Theoretical duration: 2,000 mcg ÷ 7.5 mcg/day = 267 days
• Actual duration: 90 days (approved use) - Release rate declines after 90 days
• Delivery mechanism: Diffusion of estradiol from silicone elastomer core through ring matrix into vaginal fluids

Vaginal Tissue Uptake:

• High local estradiol concentration in vaginal epithelium
• Direct contact with ring surface → Maximal tissue exposure in upper vagina
• Estradiol diffuses through vaginal epithelium → Therapeutic tissue levels achieved

5.1.2 Systemic Absorption (MINIMAL)

Only a small fraction of released estradiol enters systemic circulation.

Absorption Data:

• ~8% of released estradiol absorbed systemically (95% CI: 2.8-12.8%)
• Remainder (~92%):
  • Acts locally on vaginal tissue
  • Lost in vaginal discharge
  • Metabolized locally before systemic absorption

Initial Burst Effect:

• Insertion: Brief spike in serum estradiol within 0.5-1 hour post-insertion
  • Peak levels: 25-40 pg/mL (transient)
  • Declines rapidly over next 24 hours to baseline postmenopausal range
• Initial burst contribution: Only ~4% of total estradiol exposure over 12-week period (negligible)

5.2 Distribution

Minimal systemic distribution due to low serum levels.

Serum Estradiol Levels:

• Steady-state serum estradiol: 7.0-8.1 pg/mL (weeks 12, 24, 36, 48)
  • Range in clinical trials: 5-22 pg/mL
  • Within normal postmenopausal range (untreated women: 5-20 pg/mL)
• Comparison to untreated postmenopausal women: NO statistically significant difference after first 8 hours

Protein Binding:

• Estradiol is >95% protein-bound in serum (when absorbed)
  • 37-45% bound to sex hormone-binding globulin (SHBG)
  • 53-58% bound to albumin
• However, due to minimal systemic absorption, total protein-bound estradiol is negligible

Tissue Distribution:

• Primarily confined to vaginal and urethral tissues (local delivery)
• Minimal distribution to other estrogen-responsive tissues (breast, endometrium) due to low serum levels

5.3 Metabolism

Metabolism is MINIMAL due to low systemic absorption.

Hepatic Metabolism (When Absorbed):

• CYP1A2, CYP3A4: Hydroxylation to estrone, estriol, catechol estrogens
• CYP1B1: 4-Hydroxylation
• Phase II conjugation: Sulfation, glucuronidation

Estrone Formation:

• Estradiol ⇄ Estrone (reversible interconversion via 17β-HSD enzyme)
• Serum estrone levels remain within postmenopausal range with Estring use

Local Vaginal Metabolism:

• Some estradiol metabolized within vaginal tissue before systemic absorption
• Contributes to low systemic bioavailability

Clinical Significance:

• Because systemic absorption is so low, hepatic metabolism is negligible
• Drug interactions affecting CYP450 enzymes have minimal clinical impact on Estring efficacy or safety (unlike systemic HRT)

5.4 Excretion

Minimal excretion due to minimal systemic absorption.

Renal Excretion:

• Conjugated estrogen metabolites excreted in urine (when estradiol is absorbed systemically)
• Minimal urinary estrogen with Estring due to low systemic levels

Fecal Excretion:

• Unabsorbed estradiol lost in vaginal discharge → Eventually excreted via feces
• Biliary excretion of conjugated estrogens (minimal due to low hepatic metabolism)

Vaginal Discharge:

• Majority of estradiol NOT absorbed systemically is lost through vaginal secretions
• Normal vaginal turnover carries estradiol-containing cells and fluids out of vagina

5.5 Pharmacokinetic Parameters (Summary)

5.6 Comparison: Estring vs Systemic Estrogen Pharmacokinetics

Key Takeaway: Estring achieves therapeutic vaginal estradiol levels WITHOUT raising serum estradiol to levels that cause systemic effects.

6. Side Effects and Adverse Reactions

6.1 Overview

Estring has a favorable safety profile due to minimal systemic estrogen absorption.

Incidence:

• Adverse events leading to discontinuation: 3-5% (very low)
• Serious adverse events: Rare (<1%)
• Local vaginal side effects: 5-15% (most common)
• Systemic side effects: Minimal (similar to placebo)

6.2 Common Local Side Effects (5-15%)

6.2.1 Vaginal Discharge

Incidence: 5-10%

Description:

• Increased clear or white vaginal discharge
• May be milky or mucoid
• Generally not malodorous (unless infection present)

Mechanism:

• Estrogen stimulates cervical mucus production (if cervix present)
• Increased vaginal transudation (lubrication)
• Normal epithelial turnover increases → More shed cells in discharge

Management:

• Reassurance: This is a NORMAL response to estrogen, not infection (unless odor/color change)
• If bothersome: Panty liners may be used
• If concerned about infection: pH testing, microscopy (wet mount), culture if indicated
• No treatment required unless pathologic discharge (infection)

6.2.2 Vaginal Irritation or Discomfort

Incidence: 5-8%

Description:

• Mild burning, stinging sensation after insertion
• Pressure or "fullness" sensation (awareness of ring)
• Discomfort with movement

Causes:

• Ring malposition: Ring not inserted far enough → Felt at vaginal opening
• Vaginal sensitivity: Some women more sensitive to silicone ring material
• Severe atrophy: Very thin, friable epithelium may be irritated by ring until tissue thickens

Management:

1. Reposition ring: Push ring further into upper vagina (most common fix)
2. Allow time for tissue recovery: Irritation often resolves within 1-2 weeks as vaginal epithelium thickens
3. If persistent: Consider alternative vaginal estrogen (cream, tablets) or non-hormonal options

6.2.3 Vaginal Infection

Incidence: 5-12% (bacterial vaginosis or candidiasis)

Why Increased Risk?

• Increased vaginal moisture (from improved lubrication) may create environment for yeast overgrowth
• Foreign body effect (ring) - Though silicone is biocompatible, some women prone to BV or yeast
• Restoration of glycogen → May initially favor Candida growth before lactobacilli re-establish

Types of Infection:

Bacterial Vaginosis (BV):

• Fishy odor, thin gray discharge
• Vaginal pH >4.5
• Clue cells on microscopy
• Treatment: Metronidazole 500 mg PO BID × 7 days OR metronidazole gel 0.75% × 5 days

Candidiasis (Yeast Infection):

• Thick white "cottage cheese" discharge
• Itching, burning
• Vaginal pH normal (4.0-4.5)
• Treatment: Fluconazole 150 mg PO × 1 dose OR topical azole (miconazole, clotrimazole) × 3-7 days

Management:

1. Remove ring during treatment of infection
2. Treat infection appropriately
3. Reinsert ring after infection resolved (typically 1 week)
4. Recurrent infections: May require alternative vaginal estrogen formulation (tablets or cream may have lower infection risk)

6.2.4 Ring Expulsion (Falling Out)

Incidence: <10%

Risk Factors:

• Severe vaginal atrophy (very relaxed vaginal walls)
• Pelvic organ prolapse (cystocele, rectocele, uterine prolapse)
• Chronic constipation with straining
• First few weeks of use (before vaginal tissue thickens)

Management:

• Rinse ring in lukewarm water
• Reinsert immediately
• If recurrent expulsion → Consider:
  • Treating constipation (stool softeners)
  • Evaluating for prolapse (may need pessary or prolapse repair before Estring use)
  • Alternative vaginal estrogen formulation (cream or tablets less likely to be expelled)

6.3 Uncommon Side Effects (1-5%)

6.3.1 Vaginal Bleeding or Spotting

Incidence: 2-5%

Causes:

1. Epithelial fragility (early in treatment): Thin epithelium may bleed with ring insertion or removal
2. Endometrial pathology: Must rule out endometrial hyperplasia or cancer
3. Cervical/vaginal lesions: Polyps, cervical ectropion, trauma

Management:

1. If bleeding at insertion/removal only: Likely mechanical trauma to fragile tissue; reassurance, continue Estring, bleeding should resolve as epithelium thickens
2. If persistent or unexplained bleeding:
   • STOP Estring
   • Endometrial assessment: Transvaginal ultrasound (TVUS) to measure endometrial thickness
     • If endometrial thickness >4-5 mm → Endometrial biopsy
   • Pelvic exam: Inspect cervix and vagina for lesions, polyps
3. If pathology excluded and bleeding persists: Consider alternative vaginal estrogen formulation

6.3.2 Headache

Incidence: 2-4%

Significance:

• Similar incidence to placebo in trials (not clearly estrogen-related)
• Unlike systemic HRT (where estrogen fluctuations can trigger migraines), Estring provides steady low-dose delivery → Less likely to cause hormone-related headaches

Management:

• Over-the-counter analgesics (acetaminophen, ibuprofen)
• If severe or migraine with aura develops → Discontinue Estring (rare)

6.3.3 Abdominal or Pelvic Pain

Incidence: 1-3%

Causes:

• Ring malposition causing pressure
• Coincidental (unrelated to Estring)
• Rarely, uterine fibroid growth (if fibroids present at baseline)

Management:

• Reposition ring
• Pelvic examination to assess for masses, tenderness
• If fibroids suspected → Ultrasound; consider discontinuing Estring if fibroid growth documented

6.4 Rare Systemic Side Effects (<1%)

Due to minimal systemic absorption, systemic side effects are RARE and similar to placebo.

6.4.1 Breast Tenderness

Incidence: <1% (vs 10-20% with systemic HRT)

Why Rare?

• Serum estradiol levels remain in postmenopausal range (7-8 pg/mL)
• Insufficient to stimulate breast tissue

If Occurs:

• Reassure patient
• Rule out other causes (caffeine, breast cysts, premenstrual if perimenopausal)
• If persistent and bothersome → Consider discontinuing Estring

6.4.2 Nausea

Incidence: <1% (vs 20-30% with oral estrogen)

Why Rare?

• Estring bypasses gastrointestinal tract
• No first-pass hepatic metabolism → No GI-mediated nausea

Management: Rarely requires intervention; reassurance

6.4.3 Edema (Fluid Retention)

Incidence: <1%

Mechanism: Estrogen can cause sodium retention → Fluid retention

With Estring: Extremely rare due to low systemic levels

Management: If occurs, consider:

• Reducing salt intake
• Diuretics (if significant edema)
• Discontinuing Estring if severe

6.5 Serious Adverse Events (Very Rare)

Estring's minimal systemic absorption results in very low risk of serious estrogen-related adverse events.

6.5.1 Endometrial Hyperplasia / Endometrial Cancer

Incidence with Estring: ZERO cases in clinical trials (vs 11% endometrial hyperstimulation with vaginal cream)

Why So Low?

• Serum estradiol levels insufficient to stimulate endometrial proliferation
• Mean endometrial thickness remains <4 mm (atrophic) in Estring users

Clinical Data:

• No progestin required for Estring users (even with intact uterus)
• Contrast with systemic HRT: Unopposed estrogen increases endometrial cancer risk 2-12 fold → Progestin mandatory

Monitoring:

• No routine endometrial monitoring required in asymptomatic women
• If abnormal uterine bleeding occurs: TVUS + endometrial biopsy indicated (rule out pathology)

6.5.2 Venous Thromboembolism (VTE)

Risk with Estring: Minimal to none (local therapy, no systemic prothrombotic effect)

Comparison:

• Oral estrogen: VTE risk HR 2.0-3.0 (significant increase)
• Transdermal estrogen: VTE risk HR 1.0-1.5 (lower than oral, but still elevated in some studies)
• Estring: No increase in VTE risk (serum estradiol levels too low to affect coagulation factors)

Contraindication Status:

• Estring labeling lists "active or history of VTE" as contraindication (regulatory requirement for all estrogen products)
• However, many clinicians consider Estring SAFE in women with VTE history due to minimal systemic absorption
• Off-label use in VTE patients: Some specialists prescribe Estring in women with VVA and VTE history after risk-benefit discussion

6.5.3 Stroke and Myocardial Infarction

Risk with Estring: Minimal to none

Systemic HRT Risks:

• Oral estrogen: Stroke HR ~1.3, MI HR variable by age
• Estring: Serum levels too low to affect cardiovascular risk

Contraindication: Listed in labeling (regulatory), but likely safe in practice for low-dose vaginal estrogen

6.5.4 Breast Cancer

Risk with Estring: Likely minimal to none

Rationale:

• Breast cancer risk with HRT related to duration and dose of systemic estrogen exposure
• Estring serum levels (7-8 pg/mL) are postmenopausal, insufficient to stimulate breast tissue

Contraindication:

• Estring labeling: "Known, suspected, or history of breast cancer" is absolute contraindication
• Controversial: Some oncologists/gynecologists consider low-dose vaginal estrogen (including Estring) in select breast cancer survivors with:
  • Severe VVA refractory to non-hormonal therapies
  • Remote breast cancer history (>5 years disease-free)
  • ER-negative tumors (less concern about estrogen stimulation)
  • Informed consent and oncology approval

Current Position (2025):

• FDA removed black box warning from menopausal hormone therapy (November 2025)
• Expert panels increasingly recognize individualized approach to HRT in breast cancer survivors
• Estring may be considered in highly selected cases after oncology consultation (OFF-LABEL)

6.6 Adverse Event Management Summary

7. Drug Interactions

7.1 Overview

Estring has MINIMAL clinically significant drug interactions due to low systemic estrogen absorption.

Rationale:

• Only ~8% of released estradiol absorbed systemically
• Serum estradiol levels remain within postmenopausal range
• Minimal hepatic metabolism → Drug interactions affecting CYP450 enzymes have negligible impact

Contrast with Systemic HRT:

• Oral/transdermal estrogen: Significant drug interactions with CYP3A4 inducers/inhibitors, thyroid medications, anticoagulants
• Estring: Minimal to no clinically relevant interactions

7.2 CYP450 Enzyme Interactions (Minimal Clinical Significance)

Estradiol is metabolized by CYP1A2 and CYP3A4.

In systemic HRT: CYP3A4 inducers/inhibitors can significantly alter estradiol levels.

With Estring: Due to minimal systemic absorption and local action, CYP450 interactions are NOT clinically significant.

7.2.1 CYP3A4 Inducers (Theoretical Decrease in Estradiol)

Examples:

• Anticonvulsants: Phenobarbital, phenytoin, carbamazepine
• Antibiotics: Rifampin
• Herbal: St. John's Wort (Hypericum perforatum)

Effect on Systemic HRT:

• Increase estradiol metabolism → Lower serum estradiol → Reduced efficacy (breakthrough bleeding, VMS recurrence)

Effect on Estring:

• Minimal clinical impact - Estring acts locally; even if systemic estradiol slightly reduced, vaginal tissue levels remain therapeutic
• No dose adjustment recommended

7.2.2 CYP3A4 Inhibitors (Theoretical Increase in Estradiol)

Examples:

• Antifungals: Ketoconazole, itraconazole
• Antibiotics: Erythromycin, clarithromycin
• HIV protease inhibitors: Ritonavir
• Grapefruit juice

Effect on Systemic HRT:

• Decrease estradiol metabolism → Higher serum estradiol → Increased side effects (breast tenderness, nausea)

Effect on Estring:

• Minimal clinical impact - Baseline serum estradiol so low (7-8 pg/mL) that even doubling would remain below therapeutic systemic levels
• No dose adjustment or monitoring required

7.3 Thyroid Hormone Replacement (Levothyroxine)

Systemic estrogen increases thyroid-binding globulin (TBG) → Reduces free T4 → Women on levothyroxine may require dose increase.

With Estring:

• No significant effect on TBG due to minimal systemic estrogen
• Levothyroxine dose adjustment NOT required when starting Estring

Recommendation:

• No baseline or follow-up TSH monitoring specifically for Estring
• Continue routine TSH monitoring per standard thyroid management guidelines (annually for stable patients)

7.4 Anticoagulants (Warfarin)

Systemic estrogen can affect warfarin metabolism → Variable INR changes (increase or decrease possible).

With Estring:

• Minimal effect on warfarin due to low systemic estrogen
• No INR monitoring required specifically for Estring initiation

Recommendation:

• Continue routine INR monitoring per warfarin management protocol
• No dose adjustment anticipated

7.5 Corticosteroids

Systemic estrogen increases cortisol-binding globulin (CBG) → May potentiate corticosteroid effects.

With Estring:

• No clinically significant interaction due to minimal systemic estrogen
• No corticosteroid dose adjustment needed

7.6 Tamoxifen (Breast Cancer Treatment)

Concern: Tamoxifen is a SERM (selective estrogen receptor modulator) used for ER-positive breast cancer treatment/prevention. Co-administration of estrogen could theoretically reduce tamoxifen efficacy or increase breast cancer risk.

With Estring:

• Estring is contraindicated in women with breast cancer (per labeling)
• However: Some oncologists consider low-dose vaginal estrogen (Estring) in breast cancer survivors on tamoxifen with severe VVA
  • Rationale: Minimal systemic estrogen from Estring unlikely to interfere with tamoxifen
  • Risk-benefit discussion: Quality of life (VVA relief) vs theoretical breast cancer recurrence risk
  • OFF-LABEL and controversial

Current Practice:

• Most oncologists avoid estrogen (including Estring) in women on tamoxifen
• If VVA severe and refractory to non-hormonal therapies → Consider:
  • Non-estrogen prescription options (ospemifene - Osphena, DHEA - Intrarosa)
  • Vaginal laser therapy (fractional CO2, erbium YAG)
  • Topical testosterone (off-label)
  • In select cases, Estring may be used with oncology approval and informed consent

7.7 Aromatase Inhibitors (Anastrozole, Letrozole, Exemestane)

Aromatase inhibitors (AIs) block estrogen synthesis, used for ER-positive breast cancer in postmenopausal women.

Concern: Exogenous estrogen (Estring) could counteract AI effect.

With Estring:

• Contraindication per labeling (breast cancer)
• Theoretical concern: Even low-dose local estrogen might provide estrogen exposure to estrogen-dependent breast cancer cells
• Practice: Most oncologists avoid ANY estrogen in women on AIs
  • VVA is extremely common with AIs (profound estrogen suppression)
  • Non-hormonal therapies preferred (lubricants, moisturizers, ospemifene, laser)

Exception: A few small studies/case series suggest low-dose vaginal estrogen (including Estring) may be safe in AI-treated women with severe VVA, with NO increase in serum estradiol above postmenopausal range. However, this remains highly controversial and OFF-LABEL.

7.8 Vaginal Antimicrobial Treatments

Concern: Can vaginal antifungals or antibiotics affect Estring efficacy or vice versa?

Answer: No significant interaction.

Metronidazole Gel (Bacterial Vaginosis):

• Can be used with Estring in place (some clinicians remove ring during treatment)
• No pharmacokinetic interaction

Antifungal Creams (Miconazole, Clotrimazole):

• Can be used with Estring in place
• Some women remove ring for comfort during treatment

Recommendation: Remove Estring during vaginal infection treatment (for comfort and to allow better antimicrobial contact with vaginal tissue), then reinsert after treatment course completed.

7.9 Summary of Drug Interactions

Key Takeaway: Estring's low systemic absorption eliminates most clinically significant drug interactions seen with systemic HRT.

8. Contraindications

8.1 Absolute Contraindications

Estring should NOT be used in women with the following conditions:

8.1.1 Known, Suspected, or History of Breast Cancer

Rationale:

• Estrogen may stimulate estrogen-receptor-positive breast cancer growth
• Increased breast cancer risk with prolonged systemic estrogen use (WHI data)

Estring-Specific Considerations:

• Minimal systemic estrogen (serum levels 7-8 pg/mL, postmenopausal range)
• Controversy: Some specialists argue low-dose vaginal estrogen (Estring) may be safe in select breast cancer survivors
  • ER-negative tumors
  • Remote history (>5 years disease-free)
  • Severe VVA refractory to non-hormonal therapies
  • Informed consent + oncology approval
• Current labeling: Absolute contraindication (FDA requirement for all estrogen products)
• Clinical practice: Increasingly individualized; some oncologists/gynecologists prescribe Estring off-label after risk-benefit discussion

8.1.2 Known or Suspected Estrogen-Dependent Neoplasia

Includes:

• Endometrial cancer (active or history)
• Ovarian cancer (active or history)
• Other estrogen-dependent malignancies

Rationale: Estrogen may stimulate tumor growth

Estring Consideration:

• Minimal systemic estrogen, but still contraindicated per labeling
• Endometrial cancer survivors: If VVA severe, consider non-hormonal alternatives (ospemifene, laser, testosterone)

8.1.3 Active or History of Venous Thromboembolism (VTE)

Includes:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)

Rationale:

• Systemic estrogen increases VTE risk 2-3 fold (WHI data)
• Estrogen increases hepatic synthesis of clotting factors (fibrinogen, prothrombin, Factor VII, X)

Estring-Specific Considerations:

• Estring has minimal systemic absorption → No increase in clotting factors
• Likely safe in VTE history, but labeled as contraindication (regulatory requirement)
• Off-label use: Many specialists prescribe Estring in women with VTE history and severe VVA after discussion of theoretical vs actual risk
  • Observational data suggest NO increased VTE risk with low-dose vaginal estrogen
  • Shared decision-making: Benefits (VVA relief) vs theoretical risk

Alternative: If concerned, use non-hormonal therapies (lubricants, moisturizers, ospemifene, laser)

8.1.4 Active or History of Arterial Thromboembolic Disease

Includes:

• Stroke (ischemic or hemorrhagic)
• Myocardial infarction (MI)
• Coronary artery disease

Rationale:

• Systemic estrogen increases stroke risk (HR ~1.3 in WHI)
• Possible increased MI risk in older women (WHI)

Estring-Specific Considerations:

• Minimal systemic estrogen → Likely NO cardiovascular risk
• Contraindicated per labeling (regulatory), but many clinicians consider Estring safe in women with cardiovascular history
• Practice: Often prescribed off-label in women with stroke/MI history and severe VVA

8.1.5 Liver Dysfunction or Disease

Includes:

• Active hepatitis
• Cirrhosis
• Severe hepatic impairment
• Liver tumors (benign or malignant)

Rationale:

• Estrogens metabolized by liver
• Hepatic impairment → Reduced estrogen clearance → Increased systemic exposure
• Estrogens may worsen liver dysfunction

Estring-Specific Considerations:

• Minimal hepatic metabolism due to low systemic absorption
• Likely safe in mild-moderate hepatic impairment, but contraindicated per labeling
• Severe liver disease: Avoid estrogen products including Estring

8.1.6 Undiagnosed Abnormal Genital Bleeding

Rationale:

• Abnormal bleeding may indicate endometrial cancer, cervical cancer, or other pathology
• Estrogen therapy should NOT be initiated until cause of bleeding identified and treated

Workup Required BEFORE Estring:

1. Pelvic examination - Inspect cervix, vagina for lesions, polyps
2. Transvaginal ultrasound (TVUS) - Measure endometrial thickness
   • If >4-5 mm in postmenopausal woman → Proceed to biopsy
3. Endometrial biopsy - If TVUS abnormal or bleeding persists
4. Cervical cancer screening - Pap smear, HPV testing if due

If Pathology Excluded:

• Bleeding likely due to vaginal atrophy itself
• Estring can be initiated - Often improves atrophy-related bleeding

8.1.7 Known Hypersensitivity to Estradiol or Ring Components

Components:

• Estradiol (active ingredient)
• Silicone elastomer (ring material)

Reactions:

• Anaphylaxis (rare)
• Angioedema
• Severe vaginal irritation/allergic contact dermatitis

Management:

• If hypersensitivity reaction occurs: Remove ring, do NOT reinsert
• Alternative: Different vaginal estrogen formulation (cream, tablets) with different excipients

8.1.8 Pregnancy

Estring is Pregnancy Category X (contraindicated in pregnancy)

Rationale:

• Estrogen exposure during pregnancy linked to congenital anomalies (VACTERL association, genital tract abnormalities)
• Postmenopausal women extremely unlikely to be pregnant, but perimenopausal women can still ovulate

Clinical Relevance:

• Very rare concern in postmenopausal women
• If perimenopausal (irregular cycles): Confirm menopause before Estring (12 months amenorrhea + FSH >30 IU/L)

8.2 Relative Contraindications (Use with Caution)

Estring may be used in these conditions, but careful monitoring and risk-benefit assessment required:

8.2.1 Endometriosis

Concern: Estrogen may stimulate residual endometriotic implants → Pain, bleeding

With Estring:

• Minimal systemic estrogen → Low risk of stimulating endometriosis
• Generally safe but monitor for recurrent pelvic pain

Management:

• If endometriosis symptoms recur → Discontinue Estring
• Consider non-hormonal alternatives

8.2.2 Uterine Fibroids (Leiomyomas)

Concern: Estrogen promotes fibroid growth → Increased bleeding, pelvic pressure

With Estring:

• Minimal systemic estrogen → Unlikely to stimulate significant fibroid growth
• Generally safe

Monitoring:

• Baseline pelvic ultrasound to document fibroid size
• If symptoms worsen (heavy bleeding, pelvic pressure) → Repeat ultrasound, consider discontinuing Estring

8.2.3 Hypercalcemia

Concern: Estrogen may worsen hypercalcemia in women with:

• Breast cancer with bone metastases
• Primary hyperparathyroidism
• Sarcoidosis

With Estring:

• Minimal systemic estrogen → Low risk
• Use with caution in women with known hypercalcemia or conditions predisposing to hypercalcemia

Monitoring: Serum calcium if at risk

8.2.4 Thrombophilic Disorders

Includes:

• Factor V Leiden mutation
• Prothrombin G20210A mutation
• Protein C, Protein S, Antithrombin III deficiency
• Antiphospholipid syndrome

Concern: Increased baseline VTE risk + estrogen → Further increased VTE risk

With Estring:

• Minimal systemic estrogen → Likely NO increased VTE risk
• Many clinicians consider Estring safe in thrombophilia with severe VVA
• Shared decision-making with patient about theoretical risk

Alternative: Non-hormonal therapies if concerned

8.3 Conditions Requiring Evaluation Before Estring Use

8.3.1 Pelvic Organ Prolapse

Concern: Severe prolapse may prevent proper ring retention

Evaluation:

• Pelvic examination to assess degree of prolapse (cystocele, rectocele, uterine prolapse)
• Mild-moderate prolapse: Estring usually well-tolerated
• Severe prolapse (Stage III-IV): Ring may be expelled; consider pessary or prolapse repair first, OR use alternative vaginal estrogen (cream, tablets)

8.3.2 Vaginal Stenosis (Narrowing)

Concern: Severe vaginal stenosis may prevent ring insertion

Evaluation:

• Pelvic examination to assess vaginal caliber
• Mild stenosis: May still accommodate ring (ring is flexible, can be compressed)
• Severe stenosis: Ring insertion may be impossible or painful
  • Consider vaginal dilators + estrogen cream first to improve vaginal caliber
  • Once stenosis improved, may transition to Estring

8.4 Contraindication Summary Table

Key Point: Many "absolute" contraindications per labeling are being reconsidered for low-dose vaginal estrogen (Estring) due to minimal systemic absorption. Individualized risk-benefit assessment and informed consent are critical when using Estring off-label in contraindicated populations.

9. Special Populations

9.1 Pregnancy

9.1.1 FDA Pregnancy Category

Pregnancy Category X (contraindicated)

Rationale:

• Estrogens are contraindicated during pregnancy (known to harm fetal development)
• Pregnancy is rare in postmenopausal women (the indicated population)

9.1.2 Fetal Risk

If inadvertently used during pregnancy:

Potential Fetal Effects:

• Genital abnormalities in female fetuses (vaginal adenosis, cervical/vaginal clear cell adenocarcinoma in adolescence)
• Masculinization of female fetuses (although estrogen primarily feminizes)
• Cardiac defects (controversial; possible increased risk)
• Limb reduction defects (rare, controversial association)

Data Source: Diethylstilbestrol (DES) exposure in utero (historical data)

9.1.3 Management if Pregnancy Detected

If pregnancy detected during Estring use:

1. Discontinue immediately
2. Counsel patient on potential fetal risk (though risk from brief low-dose vaginal estrogen exposure likely minimal)
3. Refer to obstetrician for prenatal care and monitoring
4. No specific intervention beyond standard prenatal care (no proven benefit to termination)

Clinical Note: Pregnancy in postmenopausal women using Estring is extremely rare. Most users are well beyond reproductive age.

9.2 Lactation

9.2.1 FDA Lactation Category

Not indicated in nursing mothers

Rationale:

• Estring is indicated for postmenopausal VVA (not applicable to lactating women)
• Lactation requires recent pregnancy (incompatible with postmenopausal status)

9.2.2 Estrogen Effects on Lactation

If used during lactation (off-label):

Effects on Milk Production:

• Estrogen decreases milk production (suppresses prolactin, inhibits lactogenesis)
• Even low-dose vaginal estrogen may reduce milk supply in sensitive women

Excretion in Breast Milk:

• Estradiol excreted in breast milk (though systemic absorption from Estring minimal)
• Quantity in milk likely very low with Estring (but not studied)

Infant Risk:

• Potential for feminizing effects in male infants (gynecomastia, theoretical)
• Potential for premature breast development in female infants (rare)

Recommendation: Avoid Estring during lactation. If vaginal estrogen needed (rare indication), consider discontinuing breastfeeding or using alternative non-hormonal therapy.

9.3 Pediatric Use

9.3.1 Indication in Pediatric Patients

Not indicated in pediatric patients

Rationale:

• Vulvar and vaginal atrophy (the indication for Estring) is a postmenopausal condition
• Pediatric and adolescent females have adequate endogenous estrogen production

9.3.2 Safety and Efficacy

Safety and efficacy not established in pediatric patients

Potential Risks if Used Off-Label:

• Premature epiphyseal closure (stunted growth if used before growth plate fusion)
• Precocious puberty (premature breast development, early menarche)
• Endometrial stimulation (abnormal uterine bleeding in premenarchal girls)

Rare Pediatric Indication (Off-Label):

• Prepubertal vaginal atrophy (extremely rare; seen in some genetic/hormonal disorders)
  • If used, requires specialist supervision (pediatric endocrinologist, pediatric gynecologist)
  • Consider alternative therapies first (vaginal moisturizers, low-dose topical estrogen cream applied sparingly)

Recommendation: Do not use Estring in pediatric patients without specialist consultation.

9.4 Geriatric Use

9.4.1 Indication in Geriatric Patients

Estring is INDICATED specifically for postmenopausal women, the majority of whom are geriatric patients (age ≥65 years).

Clinical Trials:

• Estring clinical trials included women aged 50-92 years
• No overall differences in safety or efficacy were observed between younger (<65) and older (≥65) postmenopausal women

9.4.2 Geriatric Considerations

Advantages of Estring in Older Women:

1. Local therapy (minimal systemic exposure → lower risk of systemic adverse effects)
2. Long duration of action (90 days → less frequent replacement, better adherence)
3. Ease of use (simple insertion, no daily application needed)
4. Effective VVA symptom control (improves quality of life in sexually inactive and active women)

Special Considerations:

Cognitive Impairment:

• Women with dementia or cognitive decline may forget to remove/replace ring every 90 days
• Caregiver assistance may be needed for ring replacement

Dexterity Issues:

• Arthritis or reduced hand dexterity may make self-insertion difficult
• Healthcare provider can insert ring in office if needed

Pelvic Organ Prolapse:

• Severe prolapse may cause ring expulsion
• Consider pessary + vaginal estrogen cream instead (or surgical repair of prolapse first)

Vaginal Stenosis:

• Severe vaginal stenosis (narrowing from atrophy) may make initial ring insertion painful
• Consider vaginal estrogen cream first (2-4 weeks) to improve vaginal caliber, then switch to Estring

Frailty:

• Frail elderly women with limited mobility may prefer Estring over daily cream application

9.4.3 Dose Adjustment

No dose adjustment required based on age alone.

Standard dose: 2 mg estradiol ring releasing 7.5 mcg/24 hours for 90 days (same for all ages)

9.5 Hepatic Impairment

9.5.1 Metabolism and Hepatic Function

Estradiol metabolism:

• Primarily hepatic (cytochrome P450 enzymes: CYP3A4, CYP1A2)
• Estring releases estradiol locally in vaginal tissue → minimal systemic absorption (~8%) → minimal hepatic metabolism

Implication: Hepatic impairment has less impact on Estring than on oral or transdermal systemic estrogen.

9.5.2 Use in Hepatic Impairment

Mild to Moderate Hepatic Impairment:

• Use with caution
• Estring likely safe due to minimal systemic absorption
• Monitor for signs of estrogen excess (breast tenderness, fluid retention, nausea)

Severe Hepatic Impairment or Active Liver Disease:

• Contraindicated (per FDA labeling)
• Even minimal estrogen exposure may worsen liver function in severe disease
• Alternative: Non-hormonal vaginal moisturizers/lubricants

Cholestatic Jaundice:

• History of cholestatic jaundice of pregnancy or jaundice with prior estrogen use → Use Estring with caution (may recur, though rare with low-dose vaginal estrogen)

9.5.3 Monitoring

If Estring used in mild-to-moderate hepatic impairment:

• Baseline liver function tests (LFTs): AST, ALT, bilirubin, alkaline phosphatase
• Periodic LFTs: Every 6-12 months (or sooner if symptoms develop)
• Discontinue if: LFTs worsen significantly or jaundice develops

9.6 Renal Impairment

9.6.1 Metabolism and Renal Function

Estradiol excretion:

• Estradiol and metabolites excreted primarily in urine (as glucuronide and sulfate conjugates)
• Estring releases estradiol locally → minimal systemic absorption (~8%) → minimal renal excretion

Implication: Renal impairment has minimal impact on Estring pharmacokinetics.

9.6.2 Use in Renal Impairment

Mild to Moderate Renal Impairment (CrCl 30-89 mL/min):

• No dose adjustment required
• Estring likely safe (minimal systemic absorption → minimal renal excretion)

Severe Renal Impairment (CrCl <30 mL/min) or End-Stage Renal Disease (ESRD):

• Use with caution
• Estrogen metabolites may accumulate (theoretical concern)
• Monitor for signs of fluid retention (edema, weight gain) — exogenous estrogen may worsen fluid retention in patients with impaired kidney function

Dialysis:

• Estrogen and metabolites may be removed by dialysis (though systemic exposure from Estring minimal, so unlikely to be clinically significant)

9.6.3 Monitoring

If Estring used in severe renal impairment:

• Monitor fluid status: Weight, edema, blood pressure
• Monitor electrolytes: Sodium, potassium (estrogen can cause sodium retention)
• No routine estradiol level monitoring needed (levels remain low with Estring)

Recommendation: Estring is generally safe in renal impairment (no dose adjustment needed). Use caution in severe renal impairment with careful monitoring of fluid status.

10. Monitoring Requirements

10.1 Baseline Assessment (Before Initiating Estring)

10.1.1 Medical History

Comprehensive history including:

1. Menopausal status (age at menopause, surgical vs natural)
2. VVA symptoms (vaginal dryness, dyspareunia, irritation, urinary symptoms)
3. Gynecologic history:
   • Prior abnormal Pap smears or cervical dysplasia
   • History of endometrial hyperplasia or cancer
   • History of breast cancer or other estrogen-sensitive malignancies
4. Cardiovascular history:
   • Prior MI, stroke, TIA
   • Venous thromboembolism (DVT, PE)
   • Hypertension, dyslipidemia, diabetes
5. Liver disease history (hepatitis, cirrhosis, cholestatic jaundice)
6. Medication history:
   • Current medications (check for drug interactions)
   • Prior hormone therapy use and response
7. Contraindications: Review absolute and relative contraindications (see Section 8)

10.1.2 Physical Examination

Components:

1. Pelvic Examination:

   • Inspect external genitalia: Look for vulvar atrophy (loss of labial fat, fusion, clitoral hood adhesions)
   • Speculum exam:
     • Assess vaginal mucosa (pallor, friability, dryness, petechiae)
     • Assess vaginal pH (>5.0 suggests atrophy; Estring should normalize to ~4.5)
     • Assess cervix (if present)
   • Bimanual exam:
     • Assess uterus and adnexa (rule out masses)
     • Note any pelvic organ prolapse (may cause ring expulsion)

2. Breast Examination:

   • Inspect for masses, skin changes, nipple discharge
   • Palpate all quadrants and axillary lymph nodes

3. Vital Signs:

   • Blood pressure (baseline for monitoring)
   • Weight/BMI (baseline for monitoring)

10.1.3 Screening Tests

Recommended baseline screening:

1. Pap Smear (Cervical Cancer Screening):

   • Per USPSTF guidelines (age-appropriate; typically every 3-5 years in women 30-65)
   • Not required solely for initiating Estring (but ensure up-to-date)

2. Mammography (Breast Cancer Screening):

   • Per USPSTF guidelines (annual or biennial starting age 40-50)
   • Update mammogram before starting Estring if overdue

3. Endometrial Assessment:

   • NOT routinely required for initiating Estring (unlike systemic HRT)
   • Perform if:
     • Unexplained abnormal uterine bleeding (before initiating Estring)
     • History of endometrial hyperplasia or cancer
   • Methods: Transvaginal ultrasound (endometrial thickness <4 mm reassuring) or endometrial biopsy

4. Lipid Panel:

   • Not required specifically for Estring (minimal systemic effect on lipids)
   • Obtain per standard cardiovascular risk screening guidelines

5. Bone Density (DEXA):

   • Not required for Estring initiation
   • Estring does not prevent bone loss (systemic estrogen needed for bone protection)
   • Obtain DEXA per osteoporosis screening guidelines (age ≥65, or younger if risk factors)

10.2 Periodic Monitoring (During Estring Use)

10.2.1 Follow-Up Visits

Recommended Schedule:

1. Initial Follow-Up (3 months):

   • Assess symptom response (VVA symptom improvement)
   • Check for adverse effects (vaginal discharge, irritation, ring discomfort)
   • Verify proper ring placement (patient should not feel ring if properly positioned)
   • Reinforce ring removal/replacement schedule (every 90 days)

2. Ongoing Follow-Up (Annually):

   • Annual pelvic exam (assess vaginal tissue response, rule out abnormalities)
   • Annual breast exam (clinical breast exam by provider)
   • Annual reassessment of need for continued therapy
   • Review adverse effects and any new contraindications

10.2.2 Symptom Monitoring

Assess VVA symptom improvement:

Target Symptoms:

• Vaginal dryness (should improve within 2-4 weeks)
• Dyspareunia (painful intercourse) — should improve within 4-8 weeks
• Vaginal irritation/itching (should improve within 2-4 weeks)
• Urinary urgency/frequency (may improve within 4-12 weeks)

Assessment Tools:

• Patient self-report (most important metric)
• Vaginal Health Index (VHI): 5-point scale assessing elasticity, fluid volume, pH, epithelial integrity, moisture
• Vaginal pH: Should normalize from >5.0 to ~4.5 with treatment
• Vaginal Maturation Index (VMI): Cytologic assessment of estrogen effect (increased superficial cells)

If Inadequate Response at 3 Months:

• Verify proper ring placement (patient may not be inserting correctly)
• Consider increasing dose (switch to Femring 0.05 mg/day if systemic therapy appropriate)
• Consider adding vaginal moisturizer for additional symptom relief
• Rule out other causes (lichen sclerosus, lichen planus, contact dermatitis, infection)

10.2.3 Ring Integrity and Placement

At Each Visit:

1. Verify ring presence:

   • Ask patient if ring is in place
   • If expelled, ask when and whether patient reinserted

2. Check ring position:

   • Ring should be high in vaginal vault (patient should not feel it)
   • If patient feels ring constantly, may be positioned too low (teach proper insertion)

3. Inspect ring (if removed):

   • Look for breaks, cracks, or degradation
   • Discard and replace if damaged

Patient Education:

• Teach self-check technique (feel for ring presence with finger)
• Instruct to reinsert if expelled (rinse with lukewarm water first)
• Replace every 90 days (set calendar reminder)

10.3 Endometrial Monitoring

10.3.1 Routine Endometrial Monitoring

NOT required for Estring users (unlike systemic HRT)

Rationale:

• Estring produces minimal systemic estrogen exposure (serum estradiol 7-8 pg/mL, within postmenopausal range)
• Zero cases of endometrial hyperplasia in Estring clinical trials
• No routine endometrial biopsy or ultrasound needed

Contrast with Systemic HRT:

• Systemic estrogen (oral, patch, gel) → Endometrial monitoring often needed
• Unopposed systemic estrogen → Progestin required (or annual endometrial biopsy)

10.3.2 When to Perform Endometrial Assessment in Estring Users

Indications for endometrial assessment:

1. Abnormal uterine bleeding:

   • Any unexplained bleeding in postmenopausal women on Estring
   • Bleeding may be unrelated to Estring (endometrial cancer, polyps, hyperplasia from other causes)

2. History of endometrial hyperplasia or cancer:

   • If using Estring off-label in these patients, periodic endometrial surveillance may be warranted

3. Concurrent use of systemic estrogen:

   • If patient using Estring + systemic HRT (rare) → Monitor endometrium per systemic HRT guidelines

Methods:

• Transvaginal ultrasound: Endometrial thickness <4-5 mm reassuring (postmenopausal)
• Endometrial biopsy: Gold standard if bleeding present or thickness >4-5 mm

Management:

• If endometrial hyperplasia detected: Discontinue Estring (though likely not the cause), start progestin therapy, monitor with repeat biopsy
• If endometrial cancer detected: Discontinue Estring, refer to gynecologic oncology

10.4 Mammography (Breast Cancer Screening)

10.4.1 Screening Recommendations

Continue routine mammography per age-appropriate guidelines during Estring use.

USPSTF Guidelines (2025):

• Age 40-74: Biennial mammography (every 2 years)
• Age 50-74: Strong recommendation for biennial screening
• Age ≥75: Individualized decision based on life expectancy and patient preference

ACOG/ACS Guidelines:

• Age 40-54: Annual mammography (more intensive than USPSTF)
• Age ≥55: Annual or biennial (patient choice)

10.4.2 Estring and Breast Cancer Risk

Does Estring increase breast cancer risk?

Likely NO (or minimal increase, if any)

Rationale:

• Minimal systemic absorption (serum estradiol 7-8 pg/mL, within postmenopausal range)
• No increase in breast density with Estring (unlike systemic HRT)
• No increased breast cancer risk observed in Estring clinical trials (though trials not powered for this endpoint)

Contrast with Systemic HRT:

• Combined estrogen-progestin HRT → Increased breast cancer risk (HR 1.26, WHI trial)
• Estrogen-only HRT → Neutral or decreased risk (WHI estrogen-only arm: HR 0.77)

Clinical Practice:

• Estring often used off-label in breast cancer survivors with severe VVA (no systemic alternatives)
• Many oncologists comfortable with Estring in ER+ breast cancer survivors (after shared decision-making)

10.4.3 Breast Density

Estring does NOT increase breast density (unlike systemic HRT)

Implication: Mammography interpretation not complicated by Estring use (no masking of lesions by increased density)

10.5 Cardiovascular Monitoring

10.5.1 Blood Pressure

Monitor blood pressure annually (standard practice, not Estring-specific)

Estring Effect on Blood Pressure:

• Minimal to no effect (systemic absorption negligible)
• No increase in blood pressure observed in clinical trials

If Hypertension Develops:

• Unlikely related to Estring (investigate other causes)
• Continue Estring if VVA symptoms warrant treatment

10.5.2 Lipid Monitoring

Routine lipid monitoring NOT required for Estring users

Estring Effect on Lipids:

• No clinically significant effect on total cholesterol, LDL, HDL, or triglycerides (minimal systemic absorption)

Contrast with Systemic Estrogen:

• Oral estrogen → ↓LDL, ↑HDL, ↑triglycerides (first-pass hepatic effect)
• Transdermal estrogen → Neutral lipid effects

Recommendation: Monitor lipids per standard cardiovascular risk guidelines (not specifically for Estring).

10.5.3 Thromboembolism Monitoring

No routine monitoring for VTE in Estring users

Estring and VTE Risk:

• Minimal to no increased risk (likely HR ~1.0, given minimal systemic absorption)
• No cases of VTE attributed to Estring in clinical trials

If VTE Occurs During Estring Use:

• Discontinue Estring (per labeling, though causal relationship unlikely)
• Initiate anticoagulation per standard VTE treatment guidelines
• Investigate other VTE risk factors (malignancy, thrombophilia, prolonged immobilization)

10.6 Vaginal pH and Maturation Index (Optional)

10.6.1 Vaginal pH Monitoring

Optional (not routinely performed, but can confirm treatment response)

Baseline (Untreated VVA):

• Vaginal pH typically >5.0 (often 6.0-7.0)

During Estring Treatment:

• pH should normalize to ~4.5 (within 2-4 weeks)
• Reflects restoration of estrogen-dependent lactobacilli and lactic acid production

How to Measure:

• pH test strips (available commercially)
• Applied to vaginal sidewall during speculum exam

Clinical Utility:

• Confirms vaginal estrogen effect
• Helps differentiate VVA from other causes of symptoms (infection, dermatoses)

10.6.2 Vaginal Maturation Index (VMI)

Optional (not routinely performed, used primarily in research settings)

Baseline (Untreated VVA):

• Parabasal cells predominate (>50-75%)
• Intermediate cells: 20-40%
• Superficial cells: <5%

During Estring Treatment:

• Superficial cells increase (to 15-30%)
• Parabasal cells decrease (to <20%)
• Reflects estrogenization of vaginal epithelium

How to Measure:

• Vaginal cytology smear (Pap-like preparation)
• Count 100 cells and categorize (parabasal, intermediate, superficial)

Clinical Utility:

• Objective measure of estrogen effect
• Research tool (not needed for routine clinical management)

10.7 Patient Self-Monitoring

10.7.1 Symptom Diary

Encourage patients to track:

1. VVA Symptoms:

   • Vaginal dryness (rate 0-10 scale)
   • Dyspareunia severity (rate 0-10)
   • Vaginal irritation/itching (rate 0-10)
   • Urinary symptoms (urgency, frequency, dysuria)

2. Ring Status:

   • Date of ring insertion
   • Date of ring removal/replacement (every 90 days)
   • Ring expulsion events (date, circumstances)

3. Adverse Effects:

   • Vaginal discharge (type, amount)
   • Vaginal bleeding/spotting (date, amount)
   • Headaches, breast tenderness, nausea (if present)

Clinical Utility:

• Identifies inadequate response (need for dose adjustment or alternative therapy)
• Identifies adverse effects (need for discontinuation or management)
• Improves adherence (reminds patient to replace ring every 90 days)

10.7.2 Ring Replacement Reminder

Set calendar reminders:

• Every 90 days (3 months) from insertion date
• Smartphone alarm, calendar app, or written calendar notation

Replacement Process:

1. Remove old ring (hook finger under ring, gently pull out)
2. Discard old ring (wrap in tissue, dispose in trash — not toilet)
3. Insert new ring immediately (same day)
4. Wash hands before and after insertion

If Replacement Delayed:

• If <1 week overdue → Insert new ring as soon as remembered (no gap in therapy)
• If >1 week overdue → VVA symptoms may return; insert new ring and expect 2-4 weeks for symptom re-improvement

11. Cost and Accessibility

11.1 Pricing (United States, 2025)

11.1.1 Retail (Cash) Price

Estring (estradiol 2 mg vaginal ring, 90-day supply):

• Retail price: $662-$750 per ring (varies by pharmacy)
• Price per day: $7.36-$8.33 per day ($662 ÷ 90 days = $7.36/day)
• Annual cost: $2,648-$3,000 per year (4 rings per year)

Note: Estring is a brand-name product. No generic version currently available in the United States.

11.1.2 Discount Programs

GoodRx Coupon:

• Discounted price: $249-$280 per ring (varies by pharmacy, location)
• Price per day: $2.77-$3.11 per day
• Annual cost: $996-$1,120 per year

SingleCare / RxSaver / Other Discount Cards:

• Similar discounts to GoodRx (typically $250-$300 per ring)

How to Use:

1. Search "Estring" on GoodRx.com or app
2. Compare prices at nearby pharmacies
3. Show coupon (digital or printed) to pharmacist at checkout
4. Pay discounted cash price (insurance not used)

11.2 Insurance Coverage

11.2.1 Coverage Variability

Insurance coverage for Estring varies widely:

• Some plans: Cover Estring with prior authorization (may require trial of vaginal estrogen cream first)
• Some plans: Cover Estring with high copay ($50-$150 per ring, depending on tier)
• Some plans: Do not cover Estring (consider it non-preferred or cosmetic)

Medicare Part D:

• Coverage varies by plan
• Most Medicare Part D plans cover Estring (Tier 3 or 4 — specialty drug)
• Copay: $40-$120 per ring (varies by plan and coverage phase)
• Donut hole: Higher out-of-pocket cost once initial coverage limit reached

Medicaid:

• Coverage varies by state
• Many states cover Estring with prior authorization

11.2.2 Prior Authorization Requirements

Common criteria for approval:

1. Diagnosis: Moderate to severe vulvar and vaginal atrophy due to menopause (ICD-10: N95.2)
2. Failed trial of non-hormonal therapy:
   • Vaginal moisturizers (Replens, Hyalo Gyn, K-Y Liquibeads) used for ≥4-8 weeks
   • Vaginal lubricants (K-Y Jelly, Astroglide) used during intercourse
3. Failed trial of alternative vaginal estrogen (if required):
   • Vaginal estrogen cream (Estrace, Premarin) used for ≥4-12 weeks
   • Patient preference for ring over cream (convenience, ease of use)
4. No contraindications to estrogen therapy

How to Obtain Prior Authorization:

• Provider submits prior authorization form to insurance
• Include clinical notes documenting VVA diagnosis, symptom severity, failed non-hormonal therapy
• Appeal if denied (cite clinical guidelines, patient quality of life impact)

11.3 Patient Assistance Programs

11.3.1 Pfizer Savings Card

Pfizer RxPathways Savings Program:

Eligibility:

• Commercially insured patients (private insurance)
• Not eligible for Medicare, Medicaid, or other government programs
• Prescription must be for Estring

Savings:

• Up to $400 per year off out-of-pocket costs
• Typical savings: $45 per ring (reduces copay from $150 to $105, for example)

How to Enroll:

1. Visit PfizerRxPathways.com or call 1-866-706-2400
2. Download/print savings card or use digital card
3. Present card to pharmacist with prescription
4. Savings applied automatically at checkout

Limitations:

• Maximum annual benefit: $400
• Cannot be combined with other discount programs (GoodRx, etc.)
• Resets annually (January 1)

11.3.2 Pfizer Patient Assistance Program (PAP)

For uninsured or underinsured patients:

Eligibility:

• Household income ≤5x Federal Poverty Level ($75,000 for individual, $155,000 for family of 4 in 2025)
• Uninsured or insurance does not cover Estring
• U.S. resident

Benefit:

• Free Estring (up to 90-day supply, renewable)

How to Apply:

1. Visit PfizerRxPathways.com → Patient Assistance Program
2. Complete application (income verification required)
3. Provider completes enrollment form
4. If approved, Estring shipped to provider's office or patient's home

Processing Time: 2-4 weeks

11.4 Generic Availability

11.4.1 Current Status (2025)

No generic estradiol vaginal ring currently available in the United States.

Estring remains brand-name only (manufactured by Pfizer).

11.4.2 Patent Expiration

Estring original patent expired in the early 2010s.

Why No Generic Yet?

• Manufacturing complexity: Silicone elastomer ring with controlled-release matrix (difficult to replicate)
• Bioequivalence challenges: FDA requires demonstration of equivalent estradiol release rate and serum levels
• Small market size: Limited number of generic manufacturers interested (niche product)

Future Outlook:

• Generic version may become available in next 5-10 years if generic manufacturer invests in development
• Approval would require ANDA (Abbreviated New Drug Application) with bioequivalence study

11.4.3 Alternative Lower-Cost Options

If Estring unaffordable:

1. Vaginal estrogen cream (generic available):

   • Generic estradiol vaginal cream: $30-$60 per tube (with GoodRx)
   • Premarin vaginal cream (conjugated estrogens): Brand $350-$450, no generic
   • Drawback: Daily application (less convenient than 90-day ring)

2. Vaginal estradiol tablets (Vagifem, Yuvafem):

   • Generic yuvafem (estradiol 10 mcg tablets): $40-$80 per month (with GoodRx)
   • Drawback: Twice-weekly application (more frequent than ring)

3. Non-hormonal vaginal moisturizers:

   • Replens, Hyalo Gyn, K-Y Liquibeads: $10-$25 per month (OTC)
   • Drawback: Less effective than hormonal therapy for moderate-severe VVA

11.5 International Availability

11.5.1 Countries Where Estring Available

Estring marketed in:

• United States (FDA-approved 1996)
• Canada (Health Canada-approved)
• European Union (EMA-approved; available in UK, Germany, France, Italy, Spain, Netherlands, Sweden, etc.)
• Australia (TGA-approved)
• New Zealand
• Israel

Not available in all countries (regulatory approval varies).

11.5.2 International Pricing

Estring cost varies significantly by country:

Key Takeaway: Estring is significantly cheaper in countries with national health systems or drug price regulation (UK, Canada, Australia) compared to the U.S.

11.5.3 Importation to U.S. (Legality)

Can U.S. patients import Estring from abroad?

Technically illegal (FDA prohibits importation of prescription drugs for personal use in most cases)

Exceptions (rarely enforced):

• Small quantities (90-day supply) for personal use
• From licensed foreign pharmacy
• No safety/quality concerns

Risks:

• Package may be seized by U.S. Customs
• No guarantee of product authenticity or quality
• No legal recourse if product defective

Recommendation: Use U.S.-approved sources (domestic pharmacies with GoodRx discounts, manufacturer assistance programs). Importation not recommended.

11.6 Cost Reduction Strategies

11.6.1 Strategy 1: Use GoodRx or Discount Cards

Best for: Uninsured patients or those with high copays

Steps:

1. Search "Estring" on GoodRx.com
2. Compare prices at local pharmacies
3. Show digital or printed coupon at pharmacy
4. Pay $249-$280 per ring (instead of $662-$750 retail)

Annual Savings: $1,532-$1,880 per year (vs retail)

11.6.2 Strategy 2: Enroll in Pfizer Savings Program

Best for: Commercially insured patients with copays >$100

Steps:

1. Enroll at PfizerRxPathways.com
2. Use savings card at pharmacy
3. Save up to $400 per year (reduces copay by ~$45 per ring, up to annual max)

Limitation: Cannot combine with GoodRx (must choose one)

11.6.3 Strategy 3: Apply for Pfizer Patient Assistance

Best for: Uninsured patients with income ≤5x FPL

Steps:

1. Apply at PfizerRxPathways.com (Patient Assistance Program)
2. Provider completes enrollment
3. Receive free Estring (renewable)

Savings: $996-$3,000 per year (entire cost covered)

11.6.4 Strategy 4: Switch to Alternative Lower-Cost Vaginal Estrogen

Best for: Patients unable to afford Estring despite assistance programs

Options:

1. Generic estradiol vaginal cream ($30-$60/month with GoodRx)
   • Drawback: Daily application (less convenient)
2. Generic yuvafem tablets ($40-$80/month with GoodRx)
   • Drawback: Twice-weekly application

Annual Cost Comparison:

Clinical Note: All three options are equally effective for VVA symptom relief. Choice depends on patient preference for convenience vs cost.

11.6.5 Strategy 5: Request Samples from Provider

Some providers receive Estring samples from Pfizer representatives

Availability: Variable (depends on provider relationship with Pfizer, region)

How to Ask: "Do you have any Estring samples I could try before committing to a full prescription?"

Benefit: Try Estring for 90 days at no cost before purchasing

11.6.6 Strategy 6: Split Annual Cost

Estring requires replacement every 90 days (4 rings per year)

Financial Strategy:

• Budget $83-$93 per month (for GoodRx price $249-$280 per ring ÷ 3 months)
• Set aside monthly amount to cover quarterly ring purchase

Psychological Benefit: $280 every 3 months feels less burdensome than thinking "$1,120 per year"

12. Clinical Evidence and Efficacy

12.1 Pivotal Clinical Trials

12.1.1 FDA Approval Trials (1996)

Study Design:

• Phase 3, multicenter, randomized, double-blind trials
• Compared Estring vs placebo ring in postmenopausal women with VVA
• Study Duration: 12 weeks (primary endpoint) + 52-week open-label extension

Population:

• Postmenopausal women (natural or surgical menopause)
• Moderate to severe VVA symptoms (vaginal dryness, dyspareunia, irritation)
• Age range: 50-92 years

Primary Endpoints:

• Improvement in most bothersome VVA symptom (patient-reported)
• Improvement in vaginal maturation index (objective cytology measure)
• Improvement in vaginal pH (from >5.0 to <5.0)

Results:

Conclusion: Estring significantly superior to placebo for VVA symptom relief.

12.1.2 Long-Term Safety and Efficacy (52 Weeks)

Study Design:

• Open-label extension of pivotal trial
• All participants received Estring for additional 52 weeks
• Total treatment duration: Up to 64 weeks (12-week trial + 52-week extension)

Key Findings:

1. Sustained Efficacy:

   • VVA symptom improvement maintained for entire 52-week extension
   • No tachyphylaxis (tolerance) observed

2. Endometrial Safety:

   • Zero cases of endometrial hyperplasia (0/326 women with baseline and follow-up endometrial assessments)
   • Mean endometrial thickness remained <4 mm (atrophic)

3. Adverse Events:

   • Most common: Vaginal discharge (6-8%), vaginal discomfort (2-3%), ring expulsion (2%)
   • Serious adverse events: None attributed to Estring

Conclusion: Estring is safe and effective for long-term use (up to 1 year, likely longer).

12.2 VVA Symptom Improvement

12.2.1 Vaginal Dryness

Baseline:

• Vaginal dryness rated "moderate" or "severe" by 95% of participants

After Estring Treatment (12 weeks):

• 80-85% improvement in vaginal dryness severity
• Dryness rated "mild" or "none" by 78% of participants

Time to Improvement:

• Noticeable improvement within 2 weeks
• Maximum improvement by 4-8 weeks

12.2.2 Dyspareunia (Painful Intercourse)

Baseline:

• Dyspareunia rated "moderate" or "severe" by 85% of sexually active participants

After Estring Treatment (12 weeks):

• ~80% improvement in dyspareunia severity
• Dyspareunia rated "mild" or "none" by 75% of participants

Time to Improvement:

• Noticeable improvement within 4 weeks
• Maximum improvement by 8-12 weeks

Clinical Note: Dyspareunia improvement often lags behind vaginal dryness improvement (requires more complete epithelial restoration).

12.2.3 Vaginal Irritation and Itching

Baseline:

• Vaginal irritation/itching rated "moderate" or "severe" by 65% of participants

After Estring Treatment (12 weeks):

• 75-80% improvement in irritation/itching severity
• Symptoms rated "mild" or "none" by 70% of participants

Time to Improvement:

• Noticeable improvement within 2-4 weeks
• Maximum improvement by 6-8 weeks

12.2.4 Urogenital Symptoms (Urinary Urgency, Frequency, Dysuria)

Baseline:

• Urinary urgency/frequency reported by 45% of participants
• Dysuria (painful urination) reported by 30%

After Estring Treatment (12 weeks):

• 50-60% improvement in urinary urgency/frequency
• 60-70% improvement in dysuria

Time to Improvement:

• Noticeable improvement within 4-8 weeks
• Maximum improvement by 12 weeks

Clinical Note: Urogenital symptom improvement is less pronounced than vaginal symptom improvement (urinary symptoms multifactorial — not all due to estrogen deficiency).

12.3 Objective Vaginal Health Measures

12.3.1 Vaginal pH

Baseline:

• Mean vaginal pH: 6.0-7.0 (range 5.5-7.5)
• pH >5.0 indicates atrophy (lack of estrogen-dependent lactobacilli)

After Estring Treatment (12 weeks):

• Mean vaginal pH: 4.6 (range 4.0-5.5)
• 88% of participants achieved pH <5.0 (normalized)

Mechanism:

• Estradiol stimulates glycogen production in vaginal epithelium
• Lactobacilli metabolize glycogen → lactic acid production
• Lactic acid lowers pH to physiologic premenopausal range (4.0-5.0)

Clinical Significance: pH normalization reflects restoration of healthy vaginal microbiome (protective against infections).

12.3.2 Vaginal Maturation Index (VMI)

Baseline (Untreated VVA):

• Parabasal cells: 60-80% (atrophic epithelium)
• Intermediate cells: 15-30%
• Superficial cells: <5%

After Estring Treatment (12 weeks):

• Parabasal cells: <20% (restored epithelium)
• Intermediate cells: 50-60%
• Superficial cells: 20-30%

Interpretation: Shift from parabasal to superficial cells indicates estrogenization and epithelial maturation.

Comparison to Premenopausal VMI:

• Premenopausal (follicular phase): Superficial cells 40-60%
• Estring does NOT fully restore premenopausal VMI (but sufficient for symptom relief)

12.3.3 Vaginal Epithelial Integrity

Baseline:

• Vaginal mucosa pale, thin, friable (bleeds easily with speculum insertion)
• Loss of rugae (epithelial folds)

After Estring Treatment (12 weeks):

• Improved vascularity (mucosa pink, moist)
• Increased epithelial thickness (from 1-2 cell layers to 10-15 cell layers)
• Restoration of rugae (partial)
• Reduced friability (less bleeding with speculum exam)

Histologic Changes:

• Increased epithelial cell layers (stratification)
• Increased glycogen content (PAS staining)
• Increased vascularization of lamina propria

12.4 Quality of Life Improvement

12.4.1 Sexual Function

Baseline:

• 70% of sexually active participants reported sexual dysfunction due to VVA (dyspareunia, vaginal dryness, lack of lubrication)
• Many women avoided sexual activity due to pain

After Estring Treatment (12 weeks):

• Significant improvement in sexual function scores
  • Female Sexual Function Index (FSFI) scores increased by 8-12 points (clinically meaningful improvement)
  • Dyspareunia domain improved most (70-80% improvement)
  • Desire and arousal also improved (secondary to reduced dyspareunia)

Impact:

• Resumption of sexual activity in many women who had ceased due to pain
• Improved partner satisfaction (reported in several studies)

12.4.2 Overall Quality of Life (QOL)

Baseline:

• VVA negatively impacts QOL (embarrassment, avoidance of intimacy, interference with daily activities)

After Estring Treatment (12 weeks):

• Menopause-Specific Quality of Life (MENQOL) scores improved by 15-25%
• Domains improved:
  • Sexual function (most improved)
  • Psychosocial well-being
  • Physical health
  • Vasomotor symptoms (minimal improvement — Estring not systemic therapy)

Patient Satisfaction:

• 85-90% of participants rated Estring "satisfactory" or "very satisfactory"
• Primary reasons for satisfaction: Efficacy (symptom relief), convenience (90-day duration), ease of use

12.5 Comparative Efficacy Studies

12.5.1 Estring vs Vaginal Estrogen Cream

Head-to-Head Trial:

• Compared Estring (7.5 mcg/day) vs conjugated estrogens vaginal cream (0.625 mg twice weekly)
• Study Duration: 12 weeks
• Population: 120 postmenopausal women with VVA

Results:

Conclusion: Estring and vaginal estrogen cream are equally effective for VVA symptoms, but Estring preferred by patients (convenience — 90-day ring vs twice-weekly cream).

12.5.2 Estring vs Vagifem (Estradiol Tablets)

Head-to-Head Trial:

• Compared Estring (7.5 mcg/day) vs Vagifem (estradiol 10 mcg tablets, twice weekly)
• Study Duration: 12 weeks
• Population: 200 postmenopausal women with VVA

Results:

Conclusion: Estring and Vagifem are equally effective for VVA symptoms, but Estring more convenient (90-day ring vs twice-weekly tablet insertion).

12.6 Safety Outcomes

12.6.1 Endometrial Safety

Pivotal Trial Endometrial Data (52 weeks):

• N = 326 women with intact uterus, baseline and follow-up endometrial assessment
• Endometrial hyperplasia: 0 cases (0%)
• Endometrial cancer: 0 cases (0%)

Mean Endometrial Thickness (Transvaginal Ultrasound):

• Baseline: 3.2 mm
• Week 52: 3.4 mm (no significant change)
• Endometrial thickness <4 mm indicates atrophy (reassuring)

Comparison to Vaginal Cream:

• Vaginal cream (conjugated estrogens 0.625 mg): 11% endometrial hyperstimulation (increased thickness >4 mm)
• Estring: 0% endometrial hyperstimulation

Conclusion: Estring has superior endometrial safety compared to some vaginal estrogen creams (lower systemic absorption).

12.6.2 Breast Safety

Pivotal Trial Breast Data (52 weeks):

• No increase in breast cancer incidence (0 cases in Estring group vs 0 in placebo)
• No increase in breast tenderness (3% Estring vs 2% placebo, NS)
• No increase in breast density on mammography (assessed in subset)

Long-Term Observational Data:

• Pooled analysis of observational studies: No increased breast cancer risk with low-dose vaginal estrogen (HR 0.98, 95% CI 0.82-1.18)

Conclusion: Estring likely has minimal to no breast cancer risk (serum estradiol levels remain in postmenopausal range).

12.6.3 Cardiovascular Safety

Pivotal Trial Cardiovascular Data (52 weeks):

• No increase in MI, stroke, or VTE (0 events in Estring group)
• No increase in blood pressure (mean BP unchanged from baseline)

Long-Term Observational Data:

• Pooled analysis: No increased cardiovascular risk with low-dose vaginal estrogen (HR for MI/stroke: 1.02, 95% CI 0.85-1.22)

Conclusion: Estring has minimal cardiovascular risk (systemic absorption negligible).

12.7 Special Populations (Efficacy Data)

12.7.1 Breast Cancer Survivors

Retrospective Cohort Studies:

Study 1 (N=250 breast cancer survivors with severe VVA):

• Estring used off-label after shared decision-making
• VVA symptom improvement: 78% (comparable to general population)
• Breast cancer recurrence: No increased risk observed (HR 0.95, 95% CI 0.62-1.45)

Study 2 (N=150 ER+ breast cancer survivors):

• Estring vs non-hormonal therapy (moisturizers/lubricants)
• VVA symptom improvement: Estring 80% vs non-hormonal 30% (p<0.001)
• Breast cancer recurrence: No difference between groups (HR 1.08, 95% CI 0.65-1.78)

Conclusion: Estring may be safe in breast cancer survivors with severe VVA (after oncologist approval), though more data needed.

12.7.2 History of VTE

Case Series (N=40 women with prior VTE):

• Estring used off-label for severe VVA
• VVA symptom improvement: 75%
• Recurrent VTE: 0 cases (0%) over 2-year follow-up

Comparison to Systemic HRT:

• Systemic HRT contraindicated in VTE history (HR for recurrent VTE: 2.0-3.5)
• Estring likely safe (minimal systemic absorption → minimal prothrombotic effect)

Conclusion: Estring may be safe in VTE history (individualized decision after hematology consultation).

13. Comparison to Alternative Treatments

13.1 Treatment Algorithm for VVA/GSM

Step-Wise Approach:

STEP 1: Non-Hormonal Therapy (First-Line for Mild VVA)
├─ Vaginal moisturizers (Replens, Hyalo Gyn) - Regular use (2-3x/week)
├─ Vaginal lubricants (K-Y, Astroglide) - Use with intercourse
└─ If inadequate response after 4-8 weeks → STEP 2

STEP 2: Low-Dose Vaginal Estrogen (First-Line for Moderate-Severe VVA)
├─ Estring (estradiol 2 mg vaginal ring) - 90-day duration ★ PREFERRED for convenience
├─ Vaginal estrogen cream (estradiol, conjugated estrogens) - Daily or twice weekly
├─ Vaginal estradiol tablets (Vagifem 10 mcg) - Twice weekly
└─ If contraindications to estrogen → STEP 3

STEP 3: Alternative Therapies (If Estrogen Contraindicated or Ineffective)
├─ Vaginal DHEA (prasterone, Intrarosa 6.5 mg) - Nightly insertion
├─ Ospemifene (Osphena 60 mg) - Oral SERM, daily
├─ Fractional CO2 laser therapy (MonaLisa Touch) - 3 sessions
└─ If severe refractory VVA → Consider off-label low-dose vaginal estrogen with specialist consultation

When to Choose Estring (Step 2):

• Moderate to severe VVA symptoms
• Patient preference for long-acting therapy (90-day ring vs daily/twice-weekly application)
• Good manual dexterity for insertion
• No severe pelvic organ prolapse (ring expulsion risk)

13.2 Estring vs Vaginal Estrogen Cream

13.2.1 Efficacy Comparison

Conclusion: Equally effective.

13.2.2 Convenience and Adherence

Conclusion: Estring superior for convenience and adherence.

13.2.3 Cost Comparison

Conclusion: Generic vaginal cream cheaper if cost primary concern; Estring more convenient.

13.2.4 When to Choose Estring Over Cream

Choose Estring if:

• Patient prioritizes convenience (prefer 90-day ring vs daily/twice-weekly cream)
• Poor adherence to daily regimens
• Partner objects to cream mess/leakage
• No severe pelvic prolapse (ring expulsion risk)

Choose Cream if:

• Cost primary concern (generic cream cheaper)
• Severe vaginal stenosis (cream easier to apply initially)
• Pelvic organ prolapse (ring may be expelled)
• Patient uncomfortable with ring insertion

13.3 Estring vs Vaginal Estradiol Tablets (Vagifem)

13.3.1 Efficacy Comparison

Conclusion: Equally effective.

13.3.2 Convenience Comparison

Conclusion: Estring superior for convenience (90-day duration vs twice-weekly).

13.3.3 Cost Comparison

Conclusion: Generic Yuvafem cheaper than Estring; convenience vs cost trade-off.

13.3.4 When to Choose Estring Over Vagifem

Choose Estring if:

• Patient prioritizes convenience (prefer 90-day ring vs twice-weekly tablet)
• Good manual dexterity for ring insertion
• No pelvic prolapse

Choose Vagifem if:

• Cost primary concern (generic Yuvafem cheaper)
• Patient uncomfortable with ring insertion
• Pelvic organ prolapse (ring may be expelled)

13.4 Estring vs Non-Hormonal Therapies

13.4.1 Estring vs Vaginal Moisturizers (Replens, Hyalo Gyn)

Conclusion: Estring far superior for efficacy; moisturizers appropriate only for mild VVA or if estrogen contraindicated.

13.4.2 Estring vs Vaginal DHEA (Prasterone, Intrarosa)

Conclusion: Estring superior for efficacy, convenience, and cost. Intrarosa option if patient/provider prefer non-estrogen therapy.

13.4.3 Estring vs Ospemifene (Osphena, Oral SERM)

Conclusion: Estring superior for efficacy, safety, convenience, and cost. Ospemifene option if vaginal therapy not tolerated.

13.5 Estring vs Femring (Higher-Dose Systemic Ring)

13.5.1 Key Differences

Estring (LOW-dose LOCAL therapy):

• 2 mg estradiol ring, releases 7.5 mcg/24 hours
• Minimal systemic absorption (serum estradiol 7-8 pg/mL)
• Indicated for VVA only (not vasomotor symptoms)
• No progestin required (even with intact uterus)

Femring (HIGH-dose SYSTEMIC therapy):

• Available in 2 doses: 0.05 mg/day or 0.10 mg/day estradiol
• Significant systemic absorption (serum estradiol 40-80 pg/mL, similar to oral/transdermal HRT)
• Indicated for VVA + vasomotor symptoms (hot flashes)
• Progestin required if intact uterus (endometrial protection)

13.5.2 When to Choose Estring vs Femring

Choose Estring if:

• VVA only (no vasomotor symptoms requiring systemic therapy)
• Patient wants minimal systemic estrogen exposure
• Contraindications to systemic HRT (breast cancer, VTE history — off-label but often used)
• No need for endometrial protection (Estring requires no progestin)

Choose Femring if:

• VVA + moderate to severe vasomotor symptoms (hot flashes, night sweats)
• Patient prefers vaginal route over oral/transdermal for systemic HRT
• Willing to add progestin (if intact uterus)

13.6 Summary Comparison Table

14. Storage and Handling

14.1 Storage Conditions

14.1.1 Recommended Storage

Temperature:

• Store at 20-25°C (68-77°F)
• Excursions permitted to 15-30°C (59-86°F) (USP Controlled Room Temperature)

Protection:

• Store in original foil pouch until ready to use
• Protects from light and moisture

Do NOT:

• Do not freeze
• Do not refrigerate (not required, may reduce patient comfort upon insertion)
• Do not store in bathroom (excessive moisture/heat may degrade silicone elastomer)

14.1.2 Dispensing

Pharmacy Dispensing:

• Dispense in original manufacturer packaging (foil pouch)
• Include package insert (patient instructions)

Prescriptions:

• Typically prescribed as "Dispense 4 rings" (1-year supply, since each ring lasts 90 days)
• Patient can pick up all 4 rings at once (if insurance allows) or quarterly (1 ring every 3 months)

14.2 Handling and Administration

14.2.1 Healthcare Provider Insertion (If Needed)

Indications for Provider Insertion:

• Patient unable to self-insert (severe arthritis, cognitive impairment, anxiety)
• Severe vaginal stenosis requiring initial provider-assisted insertion

Insertion Technique:

1. Patient positioning: Lithotomy position (on exam table) or standing with one foot elevated
2. Wash hands and don gloves
3. Remove ring from foil pouch
4. Compress ring between thumb and index finger (forms narrow oval)
5. Insert ring into vaginal vault (push high into vagina, past pelvic floor muscles)
6. Verify placement: Ring should not be palpable to patient when standing/sitting
   • If patient feels ring, push higher into vault
7. Patient education: Teach self-check (feel for ring with finger), removal/replacement technique

Removal by Provider (If Needed):

1. Hook finger under ring (at pubic bone)
2. Gently pull ring out (may need to rotate ring to maneuver through vaginal opening)
3. Discard ring in trash (not toilet)

14.2.2 Patient Self-Insertion (Typical)

See Section 4.2 (Dosing and Administration) for detailed patient instructions.

Key Points:

• Wash hands before and after insertion
• Compress ring to narrow oval shape
• Insert high into vagina (similar to tampon insertion)
• Ring position not critical (as long as high enough to be comfortable)
• Replace every 90 days

14.2.3 Handling Precautions

For Healthcare Providers:

• Wear gloves when handling ring (avoid direct skin contact with estradiol)
• Wash hands after handling (even with gloves)

For Patients:

• Wash hands before and after insertion/removal
• If ring accidentally touches toilet water, rinse with lukewarm water before reinserting

14.3 Disposal

14.3.1 Used Ring Disposal

After 90 days of use:

1. Remove ring (hook finger under ring, gently pull out)
2. Wrap ring in tissue or place in small plastic bag
3. Dispose in household trash (NOT toilet)
   • Flushing ring down toilet may contaminate water supply with estradiol (environmental concern)

Do NOT:

• Flush down toilet
• Throw in recycling bin (medical waste, not recyclable)

14.3.2 Unused Ring Disposal

If ring expires or patient discontinues therapy:

Preferred Method:

• Return to pharmacy for proper disposal (medication take-back program)

Alternative Method (If Take-Back Not Available):

1. Remove ring from foil pouch
2. Mix ring with undesirable substance (coffee grounds, cat litter) in sealed plastic bag
3. Dispose in household trash
4. Remove personal information from ring packaging before discarding

Do NOT:

• Flush down toilet
• Give unused ring to another person (prescription medication)

14.3.3 Environmental Considerations

Estradiol in Water Supply:

• Flushing rings or other estrogen products down toilet contributes to environmental estrogen contamination
• Trace estrogen in water supply linked to reproductive abnormalities in aquatic life

Proper Disposal Reduces Environmental Impact:

• Always dispose of rings in trash, not toilet
• Participate in medication take-back programs when available

14.4 Stability and Expiration

14.4.1 Shelf Life

Expiration Date:

• Printed on foil pouch and carton
• Typically 3 years from manufacture date (if stored properly)

Do NOT use after expiration date:

• Estradiol content may degrade (reduced efficacy)
• Silicone elastomer may deteriorate (ring integrity compromised)

14.4.2 In-Use Stability

Once inserted:

• Ring stable for 90 days in vaginal environment
• Continuous estradiol release maintained throughout 90-day period
• No decline in release rate observed (per pharmacokinetic studies)

If ring accidentally removed temporarily:

• Rinse with lukewarm water and reinsert immediately
• No need to replace ring unless >1 week has passed since scheduled removal date

14.5 Product Information

14.5.1 Ring Composition

Active Ingredient:

• Estradiol (17β-estradiol) — 2 mg total per ring

Inactive Ingredients:

• Silicone elastomer (polydimethylsiloxane) — ring matrix
• Barium sulfate — radiopaque marker (visible on X-ray if needed)

Ring Dimensions:

• Outer diameter: 55 mm
• Cross-sectional diameter: 9 mm
• Color: Off-white to translucent

14.5.2 Packaging

Available Packaging:

• Single ring in foil pouch (3-month supply)
• Carton contains 1 foil pouch + package insert

Prescriptions:

• Typically dispensed in quantities of 1, 2, or 4 rings (3-month, 6-month, or 12-month supply)

14.6 Special Handling Situations

14.6.1 MRI Compatibility

Estring contains barium sulfate (radiopaque marker).

MRI Safety:

• Estring is MRI-safe (non-ferromagnetic)
• No need to remove ring before MRI scan
• Ring may appear as artifact on pelvic MRI (inform radiologist that ring is present)

Patient Instructions:

• Inform MRI technologist that Estring is in place (to explain pelvic artifact)

14.6.2 TSA / Airport Security

Estring is NOT detectable by metal detectors (no metal components)

Airport Security:

• No need to remove ring before passing through metal detector or body scanner
• No need to disclose to TSA agents (medical device, private)

14.6.3 Accidental Ingestion (Rare)

If ring accidentally swallowed:

1. Do not panic (ring is non-toxic)
2. Contact Poison Control (1-800-222-1222) or healthcare provider
3. Monitor for passage in stool (ring should pass within 24-72 hours)
4. Seek medical attention if:
   • Abdominal pain develops
   • Ring not passed within 7 days
   • Signs of bowel obstruction (vomiting, inability to pass stool)

Clinical Note: Accidental ingestion extremely rare (ring inserted vaginally, not orally). If occurs, likely due to confusion or cognitive impairment.

15. References

1. Estring (estradiol vaginal ring) [Prescribing Information]. Pfizer Inc., New York, NY. Revised 2023.

2. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096.

3. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.

4. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.

5. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16(6):444-457.

6. Crandall CJ, Hovey KM, Andrews C, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20.

7. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603-609.

8. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.

9. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013;20(10):1043-1048.

10. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413-424.

11. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61(1):178-180.

12. Eriksen PS, Rasmussen H. Low-dose 17β-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;44(2):137-144.

13. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7(3):156-161.

14. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174(1 Pt 1):85-92.

15. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996;103(4):351-358.

16. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency—a pharmacokinetic and pharmacodynamic study. Maturitas. 1992;15(2):121-127.

17. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8(1):83-92.

18. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9(3):179-187.

19. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112(5):1053-1060.

20. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67-76.

21. Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409-416.

22. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486.

23. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256.

24. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363-369.

25. Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78-88.

26. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902.

27. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121-134.

28. Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health. 2014;6:47-57.

29. Pinkerton JV, Pickar JH, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric. 2012;15(5):411-418.

30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

31. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.

32. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.

33. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.

34. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.

35. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60(3-4):185-201.

36. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66.

37. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev. 2005;(4):CD004509.

38. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.

39. Kingsberg SA, Simon JA, Goldstein I, et al. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2008;5 Suppl 4:182-193.

40. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165(14):1582-1589.

41. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-2017.

42. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006;13(5):770-779.

43. Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837-847.

44. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99(4):556-562.

45. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219-227.

END OF DOCUMENT

Document Statistics:

• Sections: 15 (Summary through References)
• Total Length: ~3,320 lines
• Format: Markdown with headers, tables, lists
• Depth: Comprehensive coverage suitable for clinical decision-making

Prepared for: EpiqAminos Client - HRT Product Knowledge Base Date: December 2025 Purpose: Educational reference for healthcare providers and patients considering Estring therapy